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Amyotrophic Lateral Sclerosis and  
Multiple Sclerosis Surveillance Annual Meeting: 
 
Issues Related to Developing a National Surveillance System and 
Registries for Amyotrophic Lateral Sclerosis and Multiple Sclerosis  
 
 
 
 
 
Introductions and Logistics 
 
Wendy E. Kaye, PhD 
Senior Epidemiologist 
McKing Consulting Corporation 
 
Dr. Kaye called the meeting to order, thanking those present for their attendance.  Following a 
review of housekeeping issues, she led participants in a round of introductions. 
 
Welcome and Opening Remarks 
 
Anne Sowell, PhD 
Associate Director for Science, Division of Health Studies 
Agency for Toxic Substances and Disease Registry 
Centers for Disease Control and Prevention 
 
Dr. Sowell extended her welcome to the attendees, thanking them for taking time out of their 
busy schedules to share their work in amyotrophic lateral sclerosis and multiple sclerosis 
surveillance and to offer guidance to CDC pertaining to the important next stages of the 
surveillance projects.  She explained that the Agency for Toxic Substances and Disease 
Registry (ATSDR) is administratively part of the Centers for Disease Control and Prevention 
(CDC), although it is a somewhat separate entity with respect to budget and regulations.  The 
Division of Health Studies (DHS) is made up of three components:  1) Surveillance and 
Registries Branch, in which the ALS and MS surveillance projects are housed; 2) Geospacial 
Research, Analysis, and Services Program, that deals with GIS issues, a very big group that 
does a lot of work for the rest of CDC, as well as some work for the Department of Health and 
Human Services (DHHS); and 3) Health Investigations Branch, which examines health effects 
caused by Superfund sites and other locations where there are environmental toxins that may 
be impacting the health of communities.  While DHS is fairly small, their work is very important 
and is of exceptional quality.  Moreover, DHS is very excited about having the ALS and MS 
projects as part of this division and believes that this will prove to be a very interesting, long-
term activity.         
 
Introductions, Welcome, and Overview of the Project and Goals 
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Overview of the Project and Goals  
 
Oleg Muravov, MD, PhD 
Medical Epidemiologist 
Principle Investigator ALS and MS Pilot Projects 
Agency for Toxic Substances and Disease Registry 
Centers for Disease Control and Prevention 
 
Dr. Muravov pointed out that throughout the years, ATSDR has funded various investigations to 
address community concerns regarding possible increases in autoimmune and immunological 
diseases.  The major limitation of the types of investigations that have been conducted is a lack 
of baseline prevalence estimates, which makes it impossible to determine whether there is an 
increase of these diseases in the community.  Given this, ATSDR funded several studies to 
determine the baseline prevalence for ALS and MS in several geographic areas.  The 
completed studies resulted in useful prevalence data; however, the studies also showed that 
gaining access to neurologists’ records is a time-consuming and costly endeavor.  In addition, 
not all neurologists would grant access to their records, creating the potential for bias.  In March 
2006, ATSDR convened a workshop to discuss the creation of a national surveillance system 
for selected neurological and autoimmune diseases.  Discussion also included the identification 
of existing registries and databases, selecting disease(s) for surveillance, and developing and 
testing methodology. 
 
The decision was made to start with ALS and MS, secure funding for pilot projects, obtain 
access to existing national data sets (e.g., Center for Medicare and Medicaid Services, 
Veterans Health Administration, Veterans Benefits Administration, and National Multiple 
Sclerosis Society), and develop and fund pilot projects.  Since the meeting in March 2006, 
ATSDR obtained funds from two different sources to fund both ALS and MS pilot projects, 
developed statements of work for the pilot projects, funded six pilot projects (e.g., four projects 
on ALS and 2 projects on MS), and held a workshop in February 2007 on Institutional Review 
Board (IRB) and Health Insurance Portability and Accountability Act (HIPAA) issues related to 
data sharing.  The pilot projects for MS include:  1) New York State Multiple Sclerosis 
Consortium Registry; and 2) North American Research Consortium on Multiple Sclerosis 
Registry.  The ALS projects include:  1) Mayo Clinic; 2) Emory University; 3) South Carolina 
Budget and Control Board; and 4) the HMO Research Network.   
 
The advantages of conducting projects in ALS and MS simultaneously include: 1) Monetary 
savings (e.g., data from CMS would have been twice as expensive if requested separately; 
preparing the data requests are expensive and time consuming: one versus two requests);  
2) More people are working on similar issues who can share ideas; 3) The ability to discuss 
progress and limitations related to the development of surveillance systems and registries for 
ALS and MS; and 4) The ability to discuss strategies for developing the surveillance systems 
and registries within the various medical settings and available administrative records. 
 
In conclusion, Dr. Muravov stated that the purpose of this meeting was to discuss the progress 
and limitations related to the development of surveillance systems and registries for ALS and 
MS; discuss strategies for developing the surveillance systems and registries within the various 
medical settings and available administrative records; and discuss next steps.  He strongly 
encouraged the pilot projects to candidly discuss the limitations, given that they are critically 
important to the success of these projects. 
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Discussion 
 
• Dr. Hornbrook inquired as to whether ATSDR could brief the attendees on the 
Congressional mandate that began this process, and whether the motivation pertained to 
the burden on society. 
 
• Dr. Kaye responded that the process was not begun by Congressional mandate.  The 
original meeting, convened to examine the potential for creating surveillance for selected 
autoimmune and neurological diseases, was planned and scheduled prior to the ALS 
legislation.  It was fortunate timing, which helped to keep the process moving forward.  The 
motivation was that ATSDR and others at CDC continued to receive questions regarding 
clusters of diseases.  The problem, particularly when dealing with hazardous wastes and 
environmental health, is that there are numerous questions pertaining to health effects.  
Such questions could not be answered because they did not have good prevalence data.  
Thus, the goal was to obtain solid prevalence and incidence data, which could subsequently 
be utilized to examine risk factors, especially with respect to environmental exposure issues.  
 
 
 
 
William Joel Culpepper II, MA, PhDc 
Associate Director for Epidemiology & Outcomes 
MS Center of Excellence, East Baltimore Veterans Affairs Medical Center (VAMC) 
Department of Epidemiology & Preventive Medicine 
School of Medicine, University of Maryland, Baltimore 
 
Mr. Culpepper defined case ascertainment as the methods and procedures designed to identify 
persons with target conditions from a large data repository (e.g., hospital, system, population) 
for purposes of conducting research and / or surveillance.  There is no accepted standard, so 
case ascertainment will vary depending upon the condition of interest and the available data 
sources.  The purpose of the case ascertainment dictates the minimum required accuracy of the 
case ascertainment method necessary to meet one’s objectives.  When cases are needed for 
epidemiologic / surveillance purposes, methods with high specificity (e.g., confidence in 
eliminating a case as being the condition of interest, but inclusion of some questionables and 
false positives) are required that will err on the side of being over-inclusive.  This is acceptable 
with respect to population studies.  When cases are needed for a specific study, such as a 
randomized controlled trial (RCT), methods with high sensitivity are required that accurately 
classify patients and that will err on the side of being over-exclusive to ensure that the cases 
entered are real cases and that extensive effort does not have to be spent on case adjudication.  
 
Once the method is determined, a decision must be made regarding which data sources will be 
utilized to identify cases:  If clinic charts are used, are they paper or electronic?  If a database is 
used, how detailed is that information?  Is it summary information or is it at the patient or 
encounter level?  Once these issues are mapped out, the definition of “caseness” can be 
operationalized.  Depending upon whether the interest is in surveillance or research, 
consideration must be given to whether cases are probable versus definite, whether there is an 
interest in one subtype of MS versus another (e.g., relapsing versus progressives or all of 
them), and whether disease duration and severity are part of the equation.  These are study- 
and project-specific types of questions.  Moreover, MS presents some unique dilemmas.  MS is 
a clinical diagnosis requiring an accumulation of evidence.  There is no single definitive test / 
Case Ascertainment from Extant Databases:  Issues and Examples 
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procedure or biomarker for making the diagnosis.  The ICD-9 coding system provides only one 
3-digit code to capture all MS diagnostic possibilities (340):  Possible (rule-out), Probable 
(diagnostic evaluation), Definite.  The ICD-9 coding system does not provide coding for subtype 
or disease severity.   
 
Mr. Culpepper shared two examples of East Baltimore Veterans Affairs Medical Center’s 
(VAMC) experience with the VHA MS Surveillance Registry (MSSR), which includes extant data 
collected prospectively, and the National MS Society Quality Indicators project run by RTI 
International.  Data from both examples are encounter-based, organized by level and setting of 
care (e.g., individual visits and in-patient admissions), provide diagnosis and procedure codes, 
and provide pharmaceutical codes.  The MS Center of Excellence was established in 2001 by a 
Congressional mandate, and was operational by 2003.  The MS Center of Excellence was 
tasked with improving the quality of and access to MS specialty care throughout the VHA; 
providing an annual description of the Veteran MS population, healthcare use, and costs; 
establishing quality indicators and benchmarks for quantifying program enhancements; and 
conducting basic and clinical research to further the basic understanding of MS and its 
treatment. 
 
The VA has a nationwide electronic record.  There is no paper record any longer.  The 
nationwide electronic record has a number of advantages.  For example, a veteran’s complete 
medical record can be pulled up in a VA facility in any state regardless of where he or she lives.  
Every week, every VA facility conducts a summary process during which every healthcare 
encounter is downloaded and transferred to the Austin, Texas automation center.  That is then 
distilled down further into a series of SAS data files which are organized by fiscal year and in-
patient / out-patient encounters.  There are two different sources of health care costing data in 
the VA.  The VA relies predominantly on the Health Economic Resource Center, which 
standardizes costs across the country and provides national numbers that allows for the 
comparison of a VA facility on the East Coast to one on the West Coast.  This is an excellent 
resource, although it does not include the ideal clinical detail.  
 
The first step was to review all in-patient and out-patient encounters (FY1998 – FY2006) and to 
select all patients with MS (ICD-9 340) listed as the primary diagnosis.  This group was labeled 
the MS User Cohort.  This cohort consisted of 34,743 patients and yielded an MS prevalence 4-
fold greater than any previously reported prevalence, which quickly indicated that there was an 
issue and that more work was needed.  To delve in deeper, the second step in the process was 
to review the Veterans Benefit Administration records for all veterans awarded a service-
connected disability for MS.  If symptom onset of MS occurs while on active duty or up to 7 
years after discharge from active duty, a soldier can submit a claim for having a service-
connected disability for MS.  This entails a detailed and thorough medical work-up, review by a 
panel of experts, and a determination regarding whether the individual has the disease in 
question, whether it occurred within the active duty window, and what percentage of disability 
the condition should warrant.  Those receiving 100% disability would receive 100% medical 
care, medications, prosthetics, et cetera.  There is also a monetary incentive in that the 
individual would receive 80% of their salary at the time of discharge for the rest of their life.  The 
fact that this process required a detailed evaluation by a panel of experts gave the MS Center of 
Excellence another indicator of a highly reliable case of MS.   
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The next step was to review the out-patient pharmacy records for all prescriptions of disease 
modifying therapies (DMT) and determine whether patients in the MS User Cohort (step one) 
had at least one encounter per year with MS listed as the primary diagnosis.  At the prescription 
level, the VA maintains all of the out-patient pharmacy utilization from 1998 through the present.   
This allowed for the identification of all patients who had ever been prescribed DMT (e.g., 
Avonex, Copaxone, Rebif, Betaseron, Mitoxantrone, and Tysabri).  While all of these efforts 
assisted in case ascertainment, concerns remained that there may still be primary progressive 
MS cases  which were actually true cases that were not being captured by service connected 
disability status or DMT use.  The VA system requires veteran’s to be seen a minimum of once 
per year to maintain their eligibility.  There is a specific evaluation they go through to determine 
whether a co-pay is indicated.  With that in mind, the investigators argued that if this was the 
case and a person had MS, at a minimum they should have had one visit per year with MS 
listed as their primary diagnosis during the years they were in the cohort.  The operational 
definition of “caseness” required one or more of the following criteria:  Service-connected 
disability for MS; Prescribed DMT; At least one encounter per year with MS as primary 
diagnosis.   
 
MS Case Ascertainment: VHA
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The results of this algorithm were compared with chart review determinations of MS diagnosis in 
VISN 5 (N=682), which includes Washington, DC; Baltimore, Maryland; and Martinsburg, West 
Virginia.  Comparing the 682 VISN 5 cases to chart reviews, 296 were found not to be MS and 
386 were found to be MS.  The primary interest was to eliminate those cases that clearly were 
not MS; however, because a proportion of patients with MS present with a clinically isolated 
syndrome, they did not want to eliminate them inadvertently.  Sensitivity was 0.93, specificity 
was 0.90, and positive predictive value was 0.88.  The overall accuracy of this method was 92% 
(e.g., roughly 92 out of 100 were accurately classified as MS versus non MS with this scenario).  
While somewhat over-inclusive, the investigators felt comfortable with this methodology 
because through time, further validations, and additional studies, they would touch a number of 
these individuals and would conduct further evaluations and screenings and rule them in or out.  
Roughly 35,000 individuals were identified only by having at least one MS encounter.  However, 
once the algorithm was applied, 17,929 (51.6%) were dropped as not being MS.  This saves an 
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enormous amount of time, money, and resources once specific studies are begun.  Of the 
16,808 (48.4%) cases remaining (termed as the MS patient cohort), 5,032 (30%) were identified 
only by one visit per year with MS as the primary diagnosis and 11,776 (70,000) were identified 
by a prescription for DMT and / or Service-connected disability for MS (SC / MS).    
 
With respect to the RTI MS case ascertainment example, Mr. Culpepper indicated that RTI was 
contracted by the National Multiple Sclerosis Society (NMSS) to convene an expert panel to 
establish quality indicators (QI) for MS care, during which 17 QIs were developed; and to 
evaluate how feasible these QIs could be measured in extant data.  The Medstat Claims 
database was used, which covers 4.5 million enrollees across 10 states.  Data sources included 
in-patient claims, out-patient and physician office claims, pharmaceutical claims, and 
demographics.  Data consisted of ICD-9 diagnosis and procedure codes and detailed 
pharmaceutical codes.  The major difference from the VA data is that Medstat does not have 
service-connected disability.  Thus, five operational definitions were evaluated:  1) D1 required 
one claim with any MS diagnosis IP or OP or DMT; 2) D2 required D1 and 18+ years old 
(because for those under 18, 340 is the strep throat code); 3) D3 required 18+ years old and 2 
DX codes for MS separated by at least 1 month or DMT; 4) D4 required 18+ years old and 2 DX 
codes for MS separated by at least 1 month, or 1 DX code for MS and DMT; and 5) D5 required 
18+ years old and 2 DX codes for MS separated by at least 1 month.  RTI chose the D3 
population from 2002 as their “baseline” denominator (“MS cases”), given that it ”represents a 
middle ground in terms of restrictiveness for MS case finding and has the benefits of the larger 
2002 sample size.”  Unfortunately, no validation (e.g., chart review) was performed.  Thus, 
reliability and accuracy of this case ascertainment method is unknown: 
 
MS Case Ascertainment: RTI
5,7364,055D5
6,2654,317D4
7,2214,810D3
9,7866,745D2
9,8886,860D1
20022001Denominator
 
 
To recap, the intent of the VHA case ascertainment was to identify MS cases for studies.  A 
focused algorithm was utilized to identify non-MS cases to avoid being too over-exclusive, and 
this required validation efforts to assess the accuracy and reliability of the algorithm.  The intent 
of the RTI case ascertainment was to identify cases for screening / surveillance for QIs.  The 
algorithm was likely over-inclusive, but no validation was performed to confirm this.  With 
respect to lessons learned, it is important to define the purpose for case ascertainment, know 
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the nuances of the data, and incorporate strategies to validate case ascertainment algorithm in 
at least a sub-sample. 
 
In terms of future work, laboratory (e.g., IgG) and radiographic findings (e.g., MRI) that the VA is 
trying to bring on line will be included.  That should help to add some precision to case 
identification.  The bottom line with case ascertainment from extant databases is that “you can 
pay now” as in the VHA strategy by designing ascertainment efforts that are front-loaded and 
performing the algorithm and validation early in the process.  With this method, the emphasis is 
on accuracy in order to avoid the time and expense of direct patient screening for “caseness.”  
Or, “you can pay later as in the RTI strategy by designing ascertainment efforts that are end-
loaded, with validation not performed or performed later via more laborious and time consuming 
methods (e.g., in clinic evaluation).  With this method, the emphasis is on identifying cases at 
the population level for screening / surveillance with validation to be done later. 
 
Discussion 
 
• Dr. Hornbrook inquired as to what would occur if someone in the VA system got cancer.  For 
example, if a veteran’s primary diagnosis was MS, but then he developed prostate cancer, 
would MS be removed as the primary diagnosis?  
 
• Mr. Culpepper responded that if the person died and came out of the cohort, for the time 
period they were included, they would have to have had at least one encounter with MS as 
the primary diagnosis.  A veteran with prostate cancer would see their oncologist, at which 
time prostate cancer would appear as the primary diagnosis.  However, when they visited 
their neurologist, MS would be the primary diagnosis and would be captured that way. 
 
• With regard to MS case ascertainment, it was noted that perhaps there were a lot of 
misdiagnoses. 
 
• Mr. Culpepper replied that there appears to be a lot of misdiagnosis occurring.  There is a 
longitudinal study underway, which is sponsored by the MS Center East, which covers 11 
sites throughout the Eastern Seaboard.  Part of that process included sending patient lists to 
each center for validation of their respective cases.  Their numbers were almost identical, 
plus or minus a few percentage points.  Typically, upon chart review, those individuals who 
have been seen only occasionally are found to have been subsequently diagnosed with 
Parkinson’s or some other disease.  Given this, it is possible that the algorithm may need to 
be revised somewhat.   
 
• Dr. Kasarskis requested further information about how the VHA cases dropped out versus 
the three criteria specified, pointing out that the business of electronic coding of one 
encounter per year by somebody as a diagnosis of MS is just one mouse click away from an 
error.   
 
• Mr. Culpepper responded that those who were identified as being cases were identified by 
the service-connected disability and DMT.  As mentioned, 5,032 (30%) were identified only 
by one visit per year with MS as the primary diagnosis and 11,776 (70%) were identified by 
a prescription for DMT and / or Service connected-disability for MS (SC / MS).  The 17,929 
(51.6%) who were excluded from the overall cohort met none of the criteria (e.g., they were 
not seen at least one time per year with MS as the primary diagnosis, they had no service-
connected disability for MS, and they were not prescribed a DMT).  The algorithm was 
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applied originally to the entire cohort of 35,000.  The 682 cases from one area were used to 
validate the algorithm, which was then applied to the entire 35,000 once validated. 
 
• An inquiry was posed regarding whether investigators learned anything from the algorithm 
and then subsequently re-taught it.   
 
• Mr. Culpepper replied that this step had not been done yet.  They are currently reviewing all 
of the validation data to determine what other pieces of information can be included in the 
algorithm.  The VA data systems are in the process of including increasingly more laboratory 
findings into their laboratory data files.  Currently, this does not include cerebral spinal fluid 
analysis.  Plans are in the work to do radiographic data in order to have summary reports 
components.  It is unknown whether they will ever have imaging available with that type of 
system, but those are a couple of components that are in the mill that certainly in time 
investigators will be able to take advantage of.  Mr. Culpepper recently completed a national 
survey to a sub-sample of the MS patient cohort of 16,808.  Approximately 1,700 responses 
have been returned.  Part of that survey was to acquire some of the clinical detail that could 
not be obtained from the administrative data.  In that survey, questions were posed about 
sub-type, date of diagnosis, symptom onset, chronological DMT history (e.g., If you stopped 
why you stopped?; If you switched, what did you switch to?; and quality of life and functional 
pieces).  The investigators are in the process of analyzing those data and comparing them 
to what has already been done in order to triangulate this.  This may also offer clues 
regarding other data elements to consider in order to make this process more precise. 
 
• It was suggested that the investigators use this to teach the informatics system how to keep 
up with disease understanding.  Otherwise, they will be stuck in medieval times. 
 
• Dr. Bejaoui indicated that the Marshfield Clinic has an MS Center with an MS specialist who 
sees over 1,000 patients per year, many of whom are presenting for a second opinion.  Of 
those, approximately 50% do not have MS.  
 
• Mr. Culpepper responded that he was not surprised given the VA experience.  The VA may 
be somewhat different in that they do not have MS specialization in every medical center 
across the VA.  Some of the determinations are being made by general practitioners, 
urologists, neurologists, and physiatrists who do not have MS specialty training, so there are 
errors in fully appreciating and recognizing symptoms for what they might or might not be. 
Another issue the MS Center is attempting to address is how to disseminate information and 
consultation to the general clinics so that when a general practitioner sees someone who 
has MS or is suspected of having MS, there is a way to obtain more detailed information and 
improve the diagnostic process.  
 
• Dr. Hoffman wondered whether there was a disincentive, as there is outside the VA, by 
including MS as a rule out diagnosis.  If that is done in order to attempt to get a private 
payer to pay for an MRI and other testing and nothing other than a symptom code is used, 
frequently they will pay for it. 
 
• Mr. Culpepper replied that this was a non-issue, given that the VA is using that as a rule out.  
In many instances, because of the way the VA is structured, they can go right to testing 
without having to acquire prior authorization, whether it will be covered by the insurance 
agency, only covered at 20%, et cetera.   
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• Dr. Hornbrook thought that coding incentives would be a theme throughout the day.  There 
are systems such as the VA and HMOs that do not require pre-authorization for testing, 
while there are other systems that do require pre-authorization resulting in very different 
diagnostic coding by physicians.   
 
• Mr. Culpepper pointed out that when ICD-11 comes out, there will be more precision in the 
diagnostic codes, with a decimal code addition to identify whether something is a rule out, 
suspected, possible, or definite. 
 
• Dr. Nelson noted that the VA cohort would be missing those patients who do not have at 
least one visit per year and who do not have any DMTs.  While this may not be a large 
subgroup, it is increasingly being recognized as under-ascertained in studies in general.   
 
• Mr. Culpepper responded that this is what they have done to date, realizing that there was a 
possibility that those individuals would be under-ascertained.  There are mild, atypical cases 
that represent a unique group to consider beyond traditional MS patients.  The hope is that 
information received from the survey will help to identify those types of individuals, will help 
to determine whether the methods are too restrictive, and / or will guide them toward 
another avenue that will help to identify these under-ascertained patients. 
 
• Dr. Nelson pointed out that they are not, however, sending the survey to the entire cohort of 
35,743 possible MS patients. 
 
• Mr. Culpepper responded that the VA is in the process of rolling out a web-based portal 
known as “My Health Vet,” which allows individuals to review their own medical records, 
change and update information, et cetera.  We plan to have a link to this site that will take 
patients to the  MS Center of Excellence site and the survey, which can be voluntarily 
completed and they can consent to be included in the surveillance registry (e.g., the mail-
based respondent surveys to date).  That may also capture some of the under-ascertained 
individuals.  He has also considered that some individuals may be seen in 1998, for 
example, do not return to the VA for the next two years, but then appear again after that.  
The algorithm would ignore those patients. 
 
• Dr. Tyry indicated that in the North American Research Committee on MS (NARCOMS) 
database, many individuals have both VA and private insurance.  It seemed to her that 
some of the individuals in the full cohort (34,743) may be diagnosed in the VA system, may 
have cancer, and may stay in the system because they see their oncologist.  However, they 
may go through the private insurance to see their MS practitioner. 
 
• Mr. Culpepper agreed, noting that they recently requested CMS data for the MS cohort to 
determine whether switching is taking place.  It is known from other chronic conditions that 
distance to a facility has a major impact; that is, the further away someone is from a VA 
facility, the more likely they are to use Medicare services, and vice versa.  The plan is to 
mine the CMS data for additional information. 
 
• Dr. Hornbrook inquired as to whether the VA examined the data with regard to whether the 
veterans were dual eligible for Medicaid.  He also wondered whether Mr. Culpepper had 
begun working with National Language Processing (NLP) to process the notes. 
 
• Mr. Culpepper responded that a data element that is completed at each encounter that 
specifies who the payer is (e.g., VA or Medicaid).  While the investigators began reviewing 
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this information, similar to the private sector, diagnosis codes are sometimes entered 
because it results in better payment.  This scenario was occurring frequently in the VA.  
Some veterans who had high co-pay and were eligible for Medicare, would get entered so 
that Medicare would pick up the bill.  If the VA paid the bill, the veteran would have a large 
co-pay for that visit.  Therefore, the investigators were not convinced that this would be a 
reliable indicator.  Once they have the CMS data, they will know with greater certainty who is 
dual eligible.  They do have a funded grant to conduct such an analysis.  With respect to 
processing the notes in the charts, although they have a group that is interested in doing 
that, it has not been done yet.  They have engaged in discussion about this with the Colon 
Cancer Registry representatives and the VA; however, the Colon Cancer Registry has a VA 
mandate and an entire programming cadre to assist them with this.                                 
 
 
 
 
 
 
Stephen K. Van Den Eeden, PhD 
Senior Investigator, Division of Research 
Kaiser Permanente—Northern California 
 
Dr. Van Den Eeden indicated that the goal of the Kaiser Permanente project was an etiological 
case-control study of ALS.  The investigators wanted to study genes among other things, so it 
was important to be as accurate about diagnosis as possible and to use newly diagnosed / 
incident cases rather than trying to find all prevalent cases and then sort them out.  Kaiser 
Permanente has a host of data systems which they can search about a single member within 
Kaiser: 
 
KPNC Members
ADT
Inpatient
AOMS
Referrals
OSCR
Outpatient
LURS
Laboratory
RAPTR
Pathology
Membership
ESRD
Registry
Benefits
Diabetes
Registry
Cancer
Registry
(KP & SEER)
CATS
Claims
PIMS
Pharmacy
MortLink
Mortality
 
 
 
The original goal was to cast a wider net, and they had reasonable good resources from recent 
National Institutes of Health (NIH) funding to sort through the wheat to find the kernels for which 
Lessons in Case Ascertainment and Confirmation  
from the Kaiser Permanente Case-Control Study of ALS 
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they were looking.  The data sources were all computerized and included complete information 
for in-patient, out-patient, provider, department, laboratory tests and results, and pharmacy 
(prescription drugs dispensed).  While the investigators often knew that a procedure was done, 
they did not always have electronic access to the results.  Clinic and in-patient records were 
available as needed in hardcopy. 
 
The Kaiser Permanente—Northern California Region (KPNC) is a group practice HMO with 
approximately 3.1 million members in the San Francisco Bay and Sacramento areas.  About 25-
30% of the geographic population is covered in KPNC.  The practice setting includes 19 hospital 
medical centers and 20 medical office buildings.  There are approximately 65 neurologists and 
physicians who work exclusively within Kaiser Permanente (KP).  Virtually all care is provided 
within KP and 100% of ALS cases are referred to neurologists.  This differs from the VA in that 
once someone is a member of Kaiser, they do receive all of their care there.   
 
The investigators used a standardized case definition, which included modified criteria proposed 
by the World Federation of Neurology Research Committee Group on Neuromuscular Disease 
[World Federation of Neurology Research Committee Research Group on Neuromuscular 
Diseases. J Neurol Sci 1988;86:333-60].  This includes evidence of Lower Motor Neuron (LMN) 
degeneration by clinical, electrophysiological, or neuropathologic examination; Upper Motor 
Neuron (UMN) degeneration by clinical examination, and progressive spread of symptoms or 
signs within a region or to other regions, as determined by history or examination together with 
absence of:  Electrophysiological and pathological evidence of other disease processes that 
might explain the signs of LMN and/or UMN degeneration, and neuroimaging evidence of other 
disease processes that might explain the observed clinical and electrophysiological signs. 
 
Searching the in-patient, out-patient, and pharmacy records, the investigators looked for anyone 
who was coded with an ALS diagnosis or motor neuron disease at any point in the electronic 
databases.  The parameter was to search for cases from January 1, 1996 through March 31, 
2000.  Anyone who had an ALS diagnosis or motor neuron disease prior to 1996 was 
immediately counted as a prevalent case.  From the January 1, 1996 through March 31, 2000 
ascertainment period, 457 ALS diagnoses of motor neuron cases were found and sent to chart 
review.  The chart review was an ascertainment process during which any notes were copied 
related to neurology, function, and / or physical therapy that might be related.  The chart 
reviewers were trained to recognize the full range of symptoms of ALS.  The results were given 
to a movement disorder specialist at the Parkinson’s Institute, who applied the case definition 
using all of the available information.  Those for which the information was insufficient were put 
on a wait list until the next time they presented, at which time the investigators acquired the new 
information.  Of the 457 cases, 217 were deemed eligible for enrollment in the study.  The data 
systems at the time, especially in the out-patient setting, were not particularly robust to rule out 
or work up diagnoses.  The electronic medical record has solved this issue.  The remaining 
suspect cases were re-reviewed for the full two years following their diagnosis in order to be 
confident that the ascertainment process at the beginning of their cases was accurate.  Of the 
217, 142 were probable cases, 51 were possible, 13 were suspect, 5 had other neurologic 
diseases, 2 had insufficient information, and 1 had onset prior to enrolling in Kaiser.  No cases 
were called “definite” because it is largely a clinical diagnosis, there is no biomarker, and those 
who died did not go to autopsy.  Some of the possible and suspect cases lacked information as 
well, particularly given that some of the subjects died after they were found to have been 
diagnosed, so there was no ability to accumulate a clinical record to meet all of the criteria.  This 
is one reason some individuals wound up in the “possible” or “suspect” categories.  They also 
linked to all of the California death certificate records to determine causes of death.  Of the 142 
probable cases, 9 were alive or had no evidence of a death certificate, 110 had a death 
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certificate that said ALS, 18 had no mention of ALS on their death certificate, and they knew 5 
were dead but could not find a death certificate linkage for them.  Of the 51 possible cases, 7 
were alive, 33 had a death certificate that said ALS, 9 had no mention of ALS on their death 
certificate, and they knew 5 were dead but could not find a death certificate linkage for them.  All 
of the remaining individuals were alive.   
 
The investigators are attempting post hoc to develop an algorithm that will allow them to acquire 
further information about how many diagnoses subjects had, whether they received DMTs, et 
cetera.  Also important to consider in ALS and MS are alternative diagnoses.  The pattern in a 
clinical record may be to see ALS several times, but then to see an alternative diagnosis.  
Sometimes this has nothing to do with the disease process, but instead pertains to how 
something is recorded in the system.  With the electronic medical record at Kaiser, this will be 
less of an issue, but historically it was a problem. 
 
Dr. Van Den Eeden concluded that even in a comprehensive and integrated data and service 
environment, this process is not easy or inexpensive.  The best determination includes a 
provision of follow-up, ideally for two or more years.  Critical decisions are needed for early 
deaths among potential cases, equivocal cases, and death certificate cases. 
 
Discussion 
 
• Dr. Hornbrook asked what Dr. Van Den Eeden thought about the notion that ALS was the 
last disease anyone wanted to attach to a patient, so that at least in the Kaiser systems, 
there was a sense of not putting this down until it was the only thing left to do.  
 
• Dr. Van Den Eeden responded that it is definitely a clinical process.  When this study was 
begun, investigators were identifying individuals who met the case definition.  However, their 
IRB required them to obtain physician permission prior to contact.  Physicians were 
essentially writing back, “not yet” even though people were clearly meeting the case criteria.  
They also found that some of the Kaiser neurologists would send their patients for case 
confirmation to a clinical expert in San Francisco, for which Kaiser was paying, so it was in 
the system. 
 
• Dr. Kasarskis asked how many of these individuals actually had a second opinion and what 
the use of Rilutek® was, the only drug approved for ALS in the Kaiser population.  For 
example, if they applied a Rilutek® filter to the potential cases, he wondered how the data 
looked.  
 
• Dr. Van Den Eeden responded that Rilutek® is routinely used.  The investigators applied a 
Rilutek® filter, aggregated across the sites, as part of the case ascertainment process.  
Anyone who had a single prescription for Rilutek® was evaluated for whether they had a 
diagnosis.  In terms of the second opinion, there are no barriers.  However, the investigators 
would not know about a second opinion for those who self-paid for one. 
 
• Mr. Culpepper noted that once the drill downs were done for the cohorts, they were still 
hitting about a 45%-48% that were actually cases by definition.  In the end, this saves a lot 
of work and resources in screening all of the potential cohort members.  
 
• Dr. Van Den Eeden agreed, pointing out that the electronic medical record should improve 
this as well.             
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New York State 
 
Barbara Teter, PhD, MPH, CHES 
Director of Research & Development 
Coordinating Office at The Jacobs Neurological Institute 
New York State Multiple Sclerosis Consortium 
 
Dr. Teter explained that the New York State Multiple Sclerosis Consortium (NYSMSC) was 
established in 1994.  It is a durable database of demographic and clinical data to promote MS 
research and enhance patient care.  Membership includes 16 sites in New York State, 14 of 
which are currently active.  The project includes 27 investigators who are MDs or PhDs and 30 
research or data coordinators who are NPs, RNs, RAs, MSWs, and PhDs.  Governance is by, 
an Executive–Financial Committee, a Scientific Review Committee, an Executive Director, and 
a Director of Research and Development and is governed by procedures and policy.  Revisions 
require membership quorum.  Currently in the database are approximately 8,500 registered MS 
patients with about 15,000 follow-up records.  Both demographic and clinical data are collected, 
so half of a registration or half of a follow-up questionnaire is for the patient to complete and the 
other half is for physicians to complete. At the current time NYSMSC and NARCOMS are 
comparing their two databases on demographic and clinical descriptive data.    
 
For the NYSMSC MS project, the deliverable dataset last name, first name, middle initial, 
maiden name, Social Security Number, day of birth, address, and zip code will be used for 
matching and linking.  The remaining variables will be turned in to ATSDR at the end of the 
project.  NYSMSC will construct a database specific to this pilot project  in which every person 
from 2001-2005 will have a unique ID number (e.g., every person from VBA, CMS, NMSS, and 
NARCOMS), so this will be an extremely large dataset.  Also included will be the first time an 
individual is identified in the database, race, sex, age, year and month of birth, and a field that 
indicates which of these databases a person appeared in.  Upon completion, the investigators 
will compare those in the NYSMSC dataset who were in one of the other databases to those 
who are not.  They will also compare CMS to NARCOMS, CMS to VBA, et cetera.  That is, 
everyone will be compared to everyone else.  NYSMSC currently has datasets for CMS 
(Medicare), VBA, VHA, and NMSS.  They do not yet have the NARCOMS dataset, given that 
they continue to work on some IRB issues.  At the end of each record a field will be provided to 
indicate the certainty of each match.  NYSMSC will also be reporting to ATSDR frequencies on 
race, sex, age groups and mean and standard deviation, number of times registered in each 
dataset, by year in question.  This will probably be reported per dataset and on the whole 
dataset.           
  
NYSMSC greatest issue is the IRB / HIPAA waiver situation.  This was the topic of the meeting 
last year.  Although access to the data is allowed without written authorization for limited data 
sets stripped of HIPAA identifiers for public health practice versus research (research being 
defined as the systematic collection and analysis of identified health data for public authority to 
generate knowledge to benefit those beyond the participating community), academic IRBs less 
often than not do not distinguish practice from research, and because NYSMSC data were 
collected under IRB oversight, all of the sites will be required to ask their individual IRB to 
review and grant waivers if required.  The use of the data represents minimal risk to database 
registrants and will not adversely affect the rights and welfare of registrants.  Relevant data 
generated from this project will be disseminated through publications and presentations.  
Overview of the MS Surveillance Projects 
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Minimal amounts of data will be used to provide information about prevalence and basic 
demographics, which is a characteristic of surveillance.  Thus, they should not have any 
problems acquiring waivers.   
 
With respect to linking the databases together, some of the problems encountered, resolved, or 
anticipated include unflattened databases; standard state codes had to be looked up; the name 
and address fields had to be built for the VBA dataset because they are all in one field; there 
were missing fields in some of the datasets; and Soundex indexing versus visual is an issue. 
NYSMSC will probably ask a programmer to look at data records who are similar by last name 
and birth date, and then they will be pulled out and examined one-by-one in order to make a 
judgment.  For protection of private health information, IRB HIPAA waivers will be obtained 
according to individual consortium site IRB reveiw.  One problem encountered is going through 
the Kaleida Health System of Western New York, which is where the coordinating office for the 
NYSMSC is located, if Dr. Teter writes an email to their sites that includes the words “data,” 
“data management,” or “spreadsheet” even in the subject line (while the email contains 
absolutely zero PHI), it is encrypted, intercepted, and returned to her—sometimes two days 
later.  Hence, they have had to find interesting ways in which to talk to one another.  Keeping 
the passwords that were downloaded to CDs, she hand carried the actual datasets to the 
analysts at the data management site. 
 
Regarding the linking test, the matching algorithm is scored as follows: 
 
• last name = 1 
• year of birth = 1 
• year of birth +/- 1 year =1/2 
• sex = 1 
• city = 1 
• state = 1 
• month of birth = 1 
• day of birth = ½ 
• first name = ½ 
• 7 is a perfect match 
 
A score of 4 might be a good match, but there are several possibilities.  Last name, year of birth, 
month of birth, and city is a score of 4, but it is not clear whether that is really as good as last 
name, year of birth, sex, and city—also a score of 4.  Or, is last name, sex, city, and state 
better?  It is not unusual for brothers or sisters to both have MS, so last name, sex, city, and 
state is probably not of the same quality.  With year of birth, it is not clear whether +/- 1 year is 
truly worth ½.  Using year of birth +/- 1 year can actually reach a qualitative value as high as 5.  
However, without first name this can reach a value of 4.5.  This could be a good match.  The 
match of last name = 1 alone is not working for this project because when they output the data 
of the matches on 1, it is merely a list of people who have the same last name.  Thus, our 
analytic team will examine this further. 
 
A preliminary test was conducted on a small subset of NYSMSC data with three datasets (VA, 
CMS, and NMSS) (n=1850) and subset with SS # (pre-HIPAA): 
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NYSMSC -BE Teter 02/26/08 8
MS Linking Test
Progress
Test with three 
datasets with 
subset 
NYSMSC 
names 
(n=1850) and 
subset with SS 
# (pre-HIPAA) :
16.34.0Total db
72.217.4Total test 
site (n=1850)
2.11.17
< 1.06.5
1.0<1.06
20.65
4
14.6< 1.03
2.8< 1.02
7.01.5
23.315.41
% 
NMSS
% 
CMS
% 
VA
Match 
Value
 
 
CMS was removed from this table because it showed 99.7% of having a match, regardless of 
the number.  A large majority of these were scores of 1; however, they did not have time prior to 
this meeting to take out the 1s in order to give revised percentages.  Another issue is that 
NYSMSC is comparing the data to 2001-2005 data in the NYSMSC dataset, but because the 
data from the other datasets given to them include those dates, NYSMSC is going to include all 
of the dates in their dataset in the case where someone leaves the neurology clinic and uses 
their VA benefits to go to a VA center in New York State.       
 
Dr. Teter explained that leverage learning meant that ultimately, in addition to public health 
practice or the national surveillance system, the knowledge gained from this surveillance pilot 
also supports a new scientific tool (e.g., a great contribution to information technology).  Dr. 
Barry Smith, SUNY-UB Informatics, wants to scientifically minimize overlap and maximize 
efficiency in the registries, for example:  1) Through an MS ontology-based integration (MSO) to 
logically define terms to enable retrieval and analysis of data, which is measurably more useful 
than queries without the MSO; and 2) To serve as a controlled vocabulary for expression in MS 
research and public health practice.  That is, any database anywhere would be able to look at 
this MSO and use it for analysis.  With that in mind, the investigators examined the NARCOMS 
and NYSMSC consortiums databases and found them to be surprisingly similar with respect to 
sex, marital status, race, educational attainment, most recent insurance type, family history, 
smoking, clinical characteristics, PDDS, EDSS, and most recent disease type.  Race is almost 
entirely Caucasian in the NYSMSC registry population. , African Americans in the NYSMSC are 
5.9% and some analyses are underway for this population.  NYSMSC plans to change who 
collects insurance information, which is currently reported by subjects, because it appears that 
people may be confused about the combination of private and Medicaid insurance.  Some 
people have Medicaid insurance that is being administered by an HMO, so they believe that 
they have combination insurance.  Registrants in NARCOMS seem to be somewhat older at 
age of on-set compared with NYSMSC registrants.   
 
With regard to the NYSMSC surveillance pilot time-line, Dr. Teter reported that the project is on 
target and the investigators hope to complete the analyses, submit reports to ATSDR by 
September 2008, and participate in decisions about dissemination of results and whether these 
will be presented as a platform for going forward with the next steps. 
Amyotrophic Lateral Sclerosis and Multiple Sclerosis Surveillance Annual Meeting                                February 26, 2008                                     Summary Report   
 18 
CMSC / NARCOMS Patient Registry 
 
Tuula Tyry, PhD, MAED 
Program Manager 
North American Research Committee on MS Registry 
 
Dr. Tyry indicated that NARCOMS is a long-term research project of a consortium of multiple 
sclerosis centers, while CMCS is a non-profit professional organization for clinicians and 
researchers who are conducting either clinical or research work in multiple sclerosis.  The 
NARCOMS project has been operating since 1993, and the administrative office is currently 
located in Phoenix.  NARCOMS collects self-report data from patients throughout the US and 
from 50 countries through mail or on-line surveys, which people are asked to update every six 
months.  For those who follow through, there is a fairly good longitudinal record of disease 
progression, treatment patterns, et cetera.  However, since it is a voluntary registry, not 
everyone updates every year, so there are gaps in the data. 
 
NACROMS overlaps with other data sets that they have been given (e.g., NMSS, VA, and 
Medicare data) to be matched with NARCOMS participants in Georgia, Minnesota, and South 
Carolina).  They were also asked to compare NARCOMS data with the NYSMSC.  NARCOMS 
is using the following variables for the preliminary matching process:  First name, last name, 
middle name / initial, maiden name, date of birth, state of residence, city, sex, and race / 
ethnicity.  Dr. Tyry stressed that the numbers she was sharing were preliminary, given that 
NARCOMS is a “living” database.  Numbers change as people report and there are new 
enrollments every day.  Important to remember about NARCOMS’ datasets is that they are both 
retrospective and prospective, so when people enroll they provide information for the past 5 to 
50 years and also provide updates.   
 
Overall, the NARCOMS database includes about 32,000 individuals.  Approximately 1,700 of 
those are in Georgia, Minnesota, and South Carolina.  In these three states, 687 participants 
report currently being on Medicare and 271 who report being veterans.  When they first 
examined the NMSS DATA, they received a list of 23,536 (Georgia, Minnesota, and South 
Carolina) of whom 1,206 were also in NARCOMS.  That means that the NMSS list captured 
about 70% of NARCOMS participants in these three states and missed 505.  The Medicare 
dataset included over 16, 625 from Georgia, Minnesota, and South Carolina.  Of those, 641 
were also in NARCOMS.  This means that Medicare data captured 93% of NARCOMS 
participants and missed only 49 participants in these three states.  The VA dataset included 
1,599 from the three states.  Of those, 179 were also in NARCOMS meaning that that list 
captured 66% of NARCOMS participants and missed only 92 veterans in these three states.  
When the three lists are combined and compared to NARCOMS, there were 1,316 who were 
also in NARCOMS meaning that together those three databases captured 77% of NARCOMS 
participants in these three states and missed 457.  For each of the states, the investigators then 
examined whether there were any major differences between those people who matched with 
the list and those who were only in NARCOMS.  Of interest for Georgia is that the missed 
group, the ones who were only in NARCOMS, are slightly younger, have had the disease for 
slightly less time, and their disability level is less.  This was similar for Minnesota and South 
Carolina as well. 
 
Also in progress is the comparison of NARCOMS data to the NYSMSC data.  Approximately 
1,970 NARCOMS participants are from the state of New York.  The cohort includes the 
following:  Female (72%), Caucasian (92%), African American (4%), College Educated (60%), 
Currently Married (48%), Private Insurance (75%), and Medicare / Medicaid only (19%).  This 
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supports the notion that NARCOMS data may biased toward those who have higher educations 
or have some college education, so they may be missing people at lower levels of education.  
The age is similar to the overall age structure in the database.  They do not have a lot of newly 
diagnosed individuals, which is an issue that may have to be addressed in order to understand 
true prevalence. 
 
Discussion      
 
• Dr. LaRocca asked for clarification regarding whether the consortium was using the 
Medicaid dataset as well. 
 
• Dr. Tyry responded that currently they only have Medicare data. 
 
• Dr. Kaye added that Medicaid data is a work in progress. The data are enormous because 
although CMS has a filter on Medicare data so that data can be ordered just by diagnostic 
disease code, they do not have the same option for Medicaid.  Therefore, Medicaid data 
must be ordered by state.  The statistician on the project, Jenny Wu, has been reviewing all 
of the data files (e.g., in-patient, out-patient, long-term care, and pharmacy) and is not 
finding that many people, at least with the ALS.  In addition, an executive decision was 
made not to review anybody under 20 in order to be able to manage the datasets, which 
more than halved the amount of data.   
 
• An inquiry was posed regarding whether the plan was to operationalize only those 
individuals who are matched across all of the datasets. 
 
• Dr. Kaye replied that that would be a decision for another day, given that other 
characteristics must be determined first (e.g., DMT, how many visits they have had, whether 
they have been to a neurologist, et cetera).  All of that is waiting until the MS data can be 
combined from both sites and the ALS data can be combined from the four locations.   
 
• Referring to the overlap in the VA dataset versus the NARCOMS dataset, Dr. Kasarskis 
wondered whether the investigators were asking whether participants received their health 
care within the VA system or if they were veterans. 
 
• Dr. Tyry responded that the 66% referred to the match with people who indicated that they 
were veterans.  About half of those stated that they also received their care from 
somewhere else.  These are likely the people who may be in the VA system because they 
have some other condition for which they make a required annual visit in order to keep their 
benefits, but they actually see a private neurologist.  All of these data can be analyzed in 
more detail.  Part of the reason she chose to present the summaries during this meeting 
was because it depended upon how they did the match.  She is comparing notes with Dr. 
Teter to ensure that they are not duplicating efforts.  It is possible that different algorithms 
are needed for the different datasets because some of them are stronger in some areas and 
some in others.   
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South Carolina 
 
Julie Royer, MSPH 
Principle Investigator 
South Carolina Budget and Control Board 
Office of Research Statistics 
 
Ms. Royer explained that the Office of Research Statistics (ORS) is under the South Carolina 
Budget and Control Board and is a service agency in South Carolina.  She is in the Health and 
Demographics Section of the ORS, which collects, processes, analyzes, and interprets health, 
demographic, and Census data in South Carolina.  They build off of existing systems to do this.  
ORS has existing partnerships with over 40 state agencies and other private entities.  The data 
arrives at ORS with identifiers, but goes through a unique identification process to link data 
systems.  A unique per individual identifier  is assigned to each observation in a data file, and 
then identifiers are removed from the data leaving statistical data files.  They have an integrated 
data system that allows them to track people across all of the various data sources , while 
protecting confidentiality at the same time.  In addition to confidentiality, one of the hallmarks of 
this system is  the data are always “owned” by the originating agency.  For anyone who wants to 
use the data, ORS must seek permission from the originating agency to use and link any of their 
data. 
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Overview of the ALS Surveillance and Registry Projects 
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ORS collects uniform billing discharge data from all South Carolina in-patient hospitalizations, 
all emergency department visits, out-patient surgical centers, birth and death certificate data 
from the health department, claims data from Medicare / Medicaid, and State Employee Health 
Services plan (Medicaid and State Employee Health plan includes prescription data).  The 
following data systems are used for the ALS surveillance system: 
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With most of these systems, ICD-9 code 335.2 to 335.29 as either primary or secondary 
diagnosis was used to identify cases for years 2001-2005.  Cases were already identified for 
ORS in the data files from ATSDR, Emory, and the South Carolina and Georgia ALS 
Association chapters.  Ms. Royer asked for all of the encounters from the datasets that they 
received from ATSDR and Emory.  In 2005, there were approximately 557,000 in-patient 
discharges from South Carolina hospitals, 1.8 million emergency department visits, 
approximately 413,000 Medicaid service recipients over the age of 18, and about 350,000 
individuals on the state health plan insurance system.  The number of ALS cases identified from 
ORS data sources included 479 from hospitalization, 170 emergency department, 207 other 
outpatient, 296 home health care, 239 Medicaid, 271 state health plan, and 354 from vital 
records.  From the Emory and ALS Association datasets, the number of cases identified 
included 28 from Emory Administrative, 12 Emory Clinic, 14 Georgia ALS Chapter, and 26 from 
the South Carolina ALS Chapter.  From CDC / ATSDR data, the number of cases identified 
included 1,426 from Medicare, 132 VHA, and 44 from VBA.  
 
The South Carolina Cohort from 2001-2005 had total cases of 2,060 unique individuals.  Of 
these, 53 cases were removed who were younger than 18 years old the first time Ms. Royer 
encountered their motor neuron disease ICD-9 code.  Most of these were found in Medicaid and 
the diagnosis code was progressive muscular atrophy or other motor neuron disease.  Another 
27 cases were removed because they were out-of-state and for purposes of this presentation, 
she removed 36 cases that were missing date of birth (VBA) and 4 that were missing a 
diagnosis (VHA).  The remaining South Carolina Cohort includes 1,940 unique individuals.  
Almost immediately when the investigators began examining the diagnosis codes for ALS they 
realized they had a problem.  They thought that some of the non-specific ALS diagnosis codes 
(e.g., the progressive muscular atrophies, unspecified MND) would be coded on a patient’s 
record while they were being diagnosed and then it would eventually end up as code 335.20 
once that case was confirmed.  However, non-ALS MND disease codes were being used to 
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describe symptoms of other diseases.  Therefore, they developed a coding scheme to best-
identify true ALS cases.  The first seven are straightforward, although ALS is the last code found 
when sorted by date of code:   
 
Description ICD9/ICD10 Codes Total 
Unspecified MND 3352 16 
ALS 33520 563 
PMA 33521 147 
PBP 33522 90 
PP 33523 153 
PLS 33524 77 
Other MND 33529 479 
ALS Late Diagnosis multiple codes, last code=33520 207 
ALS Unsure multiple codes, last code≠33520 90 
MND Unsure, Not 
ALS 
multiple codes, no code≠33520 112 
ALS change to PLS 33520, 33524 6 
 
The South Carolina cohort, with all MND diagnosis codes are 51% male (980), 49% female 
(960), 76% Caucasian (1,478), 19% African American (357), and 5% of other / unknown race. 
With respect to age, 2% (44) are 19-34, 5% (95) are 31-40, 13% (247) are 41-50, 17% (331) are 
51-60, 24% (479) are 61-70, 26% (499) are 71-80, and 13% (245) are 80+.  Studies have 
shown that in younger age groups, more men than women are affected, but as age increases 
numbers even out somewhat.  The next slide shows the South Carolina ALS Cohort age-by-sex 
distribution for ALS or late ALS coded cases.    
 
Age Male Female Total 
19-30 7 6 13 
31-40 24 12 36 
41-50 56 39 95 
51-60 72 47 119 
61-70 122 89 211 
71-80 119 94 213 
80+ 40 43 83 
Total 440 330 770 
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Using all MND diagnosis codes 1,129 cases were identified in one dataset, 370 in two datasets, 
210 in three datasets, 123 in four datasets, 82 in five datasets, 23 in six datasets, and 3 in 
seven datasets.  When selecting only cases coded  as ALS or late ALS only 265 were identified 
in one dataset (30 UB, 17 Medicaid, 13 SHP, 6 HH, 161 Medicare, 24 VA, 8 GA Chapter, 6 SC 
Chapter), 159 in two datasets, 144 in three datasets, 108 in four datasets, 70 in five datasets, 
22 in six datasets, and 2 in seven datasets.  With respect to prevalence by year, including only 
those cases coded as  ALS or late ALS in the analysis seems to more closely reflect the 
prevalence estimate that would be expected.  Unconfirmed prevalence per 100,000, from the 
South Carolina ALS Cohort  data sources, was 8.4 in 2001; 7.8 in 2002; 8.1 in 2003; 83 in 2004; 
and 8.3 in 2005.  
 
All of the cases, regardless of source, were linked to the South Carolina in-patient and 
emergency department discharge billing data files.  If a South Carolina in-patient or emergency 
department record existed for a case and it was either following the initial motor neuron disease 
diagnosis or within a six month time period prior to that initial diagnosis date, it was requested 
for abstraction.  Cases could have more than one record, so an algorithm was used to 
determine the best record for review.  Sometimes there was a tie, so Ms. Royer requested a few 
more records than she had individual cases.  Almost half of the records requested were the 
primary source that identified the case for inclusion in the cohort.  In total 1,186 records were 
requested on 1,172 individuals (888 Inpatient records, 298 ED records, 547 primary source of 
MND code).  The following slide reflects the cases identified and the number of records 
requested: 
 
 
Description 
 
Total  Cases 
# Records 
Requested 
Unspecified MND 16 5 
ALS 563 400 
PMA 147 112 
PBP 90 77 
PP 153 120 
PLS 77 42 
Other MND 479 136 
ALS Late Diagnosis 207 157 
ALS Unsure 90 57 
MND Unsure, Not ALS 112 77 
ALS change to PLS 6 3 
 
Early on, they realized that codes 335.29 and 335.2 were not being used for suspected ALS 
cases before a definitive diagnosis was made, as one would expect.  Thus, not as many records 
as available were requested in those two categories.  Instead a random sample was selected.  If 
a record existed for the other MND codes (335.20, 335.22, 335.24, ALS late diagnosis or ALS 
unsure), it was requested for abstraction.   
 
Regarding preliminary results, not all of the records abstracted are in electronic form and not all 
have been reviewed by a neurologist at this point.  South Carolina did not use El Escorial 
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criteria to categorize cases for this presentation because there is not enough clinical data 
available in the in-patient and ED charts to consistently do so.  Instead ORS categorized cases 
based on Dr. David Stickler “gestalt” review of the case.  Dr. Stickler is the director of the ALS 
clinic at the Medical University of South Carolina.    An example of a “not enough information” 
case would be a patient who is admitted for pneumonia, ALS is documented in the chart but 
details regarding who made the diagnosis are not available, a neurology consultation was not 
obtained during the admission and Rilutek® is not listed under medications.  An example of a 
“possible/probable” ALS case for ORS would be a patient who presented to the emergency 
department for a fall, ALS is documented in the chart under past medical history, and Rilutek® 
is listed in the medication list.  Instances when clinical information is available or a patient is 
followed in an ALS clinic, or a patient is seen by a neurologist and carries a diagnosis of ALS, 
they are classified as “true” ALS cases.   Again in-patient and emergency department visit 
records lacked clinical information needed to categorize the majority of patients using El 
Escorial criteria.  Patients presented to South Carolina hospitals because of end-of-life issues, 
falls or other injuries or because they were having a PEG or trach placed.  One hundred and 
thirty-five abstracted records coded in ORS data sources as ALS or late ALS have been 
reviewed by a neurologist.  Of those, 51 were deemed “no” or “not enough data to confirm,” 36 
were “possible” or “probable,” and 48 were considered “true” cases.  The 51 “no” cases came 
from the following datasets:  1 VHA; 26 Medicare; 10 from a combination of Medicare, Medicaid 
and SHP; 14 from a combination of uniformed billing (UB), Medicare, Medicaid, SHP, VHA, 
VBA, and SC Chapter; a diagnosis of ALS was found in the chart when the record was 
abstracted in 9/14 (64%) instances when the case was identified from a UB data source.  In the 
other 37 instances the case was identified from a non-UB data source and a diagnosis of ALS 
was found only one time (3%) in the abstracted record. 
 
For progressive muscular atrophy (335.21), 39 cases have been reviewed to date.  None of 
these appear to be potential ALS cases.  Other diagnoses listed in the medical record include: 
post-polio syndrome, muscular dystrophy, CVA, brain and spinal tumors, and progressive 
supranuclear palsy.  For progressive bulbar palsy (335.22), 27 cases have been reviewed to 
date with 2 possible ALS cases.  Other diagnoses listed in the medical record include: bulbar 
neuropathy, CVA, myasthenia gravis, and progressive supranuclear palsy.  For pseudobulbar 
palsy (335.23), 48 cases have been reviewed.  Other diagnoses listed in the medical record 
include CVA, dementia, and progressive supranuclear palsy.  For primary lateral sclerosis 
(335.24), 17 cases have been reviewed, with 6 deemed probable PLS.  Other diagnoses 
include: Parkinson’s, spinal hematoma, limb pain, and falls.  For motor neuron disease other 
(335.29), 83 cases have been reviewed.  Diagnoses listed in the medical record include multiple 
sclerosis, Parkinson’s, post-polio syndrome, dementia, fibromyalgia, migraines, depression, and 
seizure disorders.  For “ALS unsure” (multiple codes identified a case including 335.20, last 
code = 335.20), 13 cases have been reviewed with 5 potential true ALS cases and 1 PLS.  
Other diagnoses include CVA, progressive supranuclear palsy, dementia, and neuropathy.  60 
“unsure MND not ALS" cases have been reviewed.  Findings include the following chart 
diagnoses: CVA, multiple sclerosis, progressive supranuclear palsy, neuropathy, lupus, 
migraines, fibromyalgia, radiculopathy, depression, Parkinson’s, and benign tremor. 
 
 
Discussion 
 
• Dr. Kasarskis noted that the field of frontal temporal dementia and motor neuron disease 
was evolving.  Some of the pseudobulbar palsy with dementia actually may have been 
motor neuron disease.  The presentation highlighted the fact that with respect to in-patient 
and emergency department records, the percentage of people who are actually hospitalized 
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is probably the minority.  Most of the work in many areas is done on an out-patient basis and 
will never be seen in a hospital code unless someone is suffering some concomitant of the 
disease (e.g., death, respiratory failure, fractures, et cetera).    
 
• An inquiry was posed regarding whether there were any roadblocks to obtaining information 
from the state. 
 
• Ms. Royer responded that there were no problems accessing the data.  While the 
investigators had to complete applications for each of the data systems used, they work 
extensively with these agencies providing data on other projects, so they  already 
understand the confidentiality measures that are in place and ORS’ ability to link and track 
cases within and across systems without identifiersl.   
 
• An inquiry was posed regarding how the individuals were identified for the chart abstraction. 
 
• Ms. Royer replied that if they had a South Carolina in-patient or emergency department visit, 
she requested them for review, except that they sampled the other motor neuron disease 
cases.  There is a statutory law in South Carolina that allows the health department to 
review medical records for endemic diseases, which is the law they utilized to review 
records further.  For this project they used in-patient and emergency department visits but 
the law also allows access to physicians’ records with their permission.  
•  
• Dr. Kaye clarified that the issues of data access had been less problematic for this project 
because all data requests have been made without asking that people be allowed to be 
contacted.  Therefore, all datasets can be reviewed, matched at the local sites, and sent 
back to ATSDR without identifiers.  How well people will cooperate at the next level remains 
to be seen.  The idea was to determine how well this type of algorithm would work, and then 
if it did, to move to the next step.  Sources have been more cooperative given the 
confidentiality of not sharing information and because there would be no contact with 
subjects. 
 
 
Georgia 
 
Michael Benatar, MD 
Principal Investigator 
Emory Department of Neurology 
 
Dr. Benatar reported that the objective of the Emory pilot project was to evaluate the feasibility 
of using existing administrative and clinical databases to identify patients with ALS in the State 
of Georgia; and determine the predictive value of ALS ICD codes for chart-reviewed validated 
diagnoses of ALS.  Data sources include:  1) Emory (e.g., Healthcare Administration, which 
tracks in-patient and out-patient records by ICD-9 codes; their large multi-disciplinary ALS 
Clinic, which has approximately 250 patient under active care at any given time and which is a 
clinical database that does not keep track of multiple visits, but simply captures that they are in 
the ALS clinic; EMG Laboratory, which tracks people based on their referring diagnosis and 
what the diagnosis seems to be based on the electrodiagnostic study; and Grady Hospital, 
which is linked to Emory, although they have not had a lot of success acquiring these data);  
2) other academic medical centers (e.g., Medical College of Georgia and Mayo Jacksonville);  
3) a few community neurologists were targeted to determine the feasibility of getting into their 
offices; 4) Centers for Medicare & Medicaid Services (CMS); 5) Veterans Administration (VA); 6) 
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ALS Association; 7) Muscular Dystrophy Association; and 8) death certificate data.  The 
advantage of the Emory ALS clinic and the EMG laboratory diagnoses is that it is known that 
these individuals have been seen by a neurologist, so there is a conclusion reached that they 
have ALS.  This is perhaps more robust than simply pulling them out of an administrative 
database.   
 
The data from Emory have been the easiest to obtain.  For the administrative database, the 
search has been by ICD-9 code, from which 1,512 patients have been identified.  This is based 
simply on the ICD-9 code, state of residence, and the years of interest for this study (2001-
2005).  From the ALS clinical database search, 1,013 patients have been identified.  The EMG 
laboratory database is relatively recent.  It has not been running for the full duration of the 
period of interest; however, this search yielded 157 addition patients from 2004-2005.  As noted, 
no data have been obtained from Grady thus far.  While the investigators have approval from 
Grady’s research oversight committee, given the Grady crisis, they have not been able to 
search their records to provide the investigators with that information.   
 
They have experienced difficulty in acquiring data out of some of the academic medical centers.  
Medical College of Georgia has theoretically been on board for almost 18 months, there have 
been numerous encounters with the IRB, and various administrative hurdles.  However, there 
has been a recent agreement to proceed.  It is not clear whether the pilot phase will come to an 
end before data are actually received from Grady, but they are still working on it.  Mayo 
Jacksonville is interested, willing, and has expressed an intent to proceed; however, there has 
been no progress yet on the IRB submission and they do not seem to want Emory’s assistance 
in preparing that.   
 
Three community neurologists were approached, all of whom agreed to provide data, but only 
two of which they heard back from in terms of getting data.  Each of the two searched their 
practice administrative databases via ICD-9 codes, with 51 patients identified from practice #1 
(49 charts abstracted) and 169 identified from practice #2 (chart abstraction pending).   
 
The Medicare data have been received for Georgia via the CDC / ATSDR.  The data are based 
on an ICD-9 code search for ALS.  This yielded 2,599 cases resident in Georgia between 2001 
and 2005.  The VA data for Georgia were also obtained via the CDC / ATSDR and include 
multiple sources of data (e.g., administrative, benefits, pharmacy).  The data are based on an 
ICD-9 code search for ALS.  This yielded 191 cases resident in Georgia between 2001 and 
2005. 
 
From the ALS Association, approval was granted to search the ALSA database under the 
auspices of the Emory IRB.  This yielded 190 subjects with ALS in Georgia between 2001-2005.  
Unfortunately, there are no charts for abstraction because the ALS Association is not providing 
care.  However, it seems reasonable to conclude that these subjects likely have ALS.  The MDA 
as an organization did not have the ability to share public health information; however, they did 
refer investigators to all of the individual MDA clinics within the state (e.g., Emory, Medical 
College of Georgia, and Roosevelt Warm Springs).  IRB approval was obtained from Roosevelt 
Warm Springs.  The Roosevelt Warm Springs database search only yielded six patients, and all 
of those charts have been abstracted. 
 
Death certificate data have also been obtained.  This was a lesson in government office, the 
various hierarchies, and the organization.  Eventually, approval was obtained for data sharing 
from the Georgia Department of Human Resources IRB.  The study was classified as exempt 
and did not really require IRB approval.  Permission was granted to search death certificate data 
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to identify cases with ALS listed as a cause of death (ICD-10).  This was a relatively 
straightforward process, with approval obtained within 6 months.  This search identified 1,435 
cases. 
 
Not a great deal of data abstraction has been done, probably about 250 charts or so, and not all 
of those have yet been verified by a neurologist.  A uniform data abstraction form was used that 
was developed collectively by the sites involved in the pilot project.  There have been a number 
of methodological difficulties, such as limited information in the chart (e.g., stated diagnosis of 
ALS, but no data to permit independent verification); single notes with no ability to document 
progression of symptoms / signs that is essential to verification of the diagnosis; and uncertainty 
regarding whether verification should be based on application of formal diagnostic criteria or a 
neurologist’s gestalt of the case. 
 
Dr. Benatar acknowledged the data management staff at the Georgia Cancer Registry for the 
tremendous assistance they provided in synthesizing and integrating the data from all of these 
sources and linking them based on their standard algorithm.  One of the difficulties with the 
diverse data sources is that very different data are received from each source.  For example, 
the clinical databases do not have Social Security Numbers or multiple dates of visit and the 
EMG database does not have a date of birth.  The breakdown of cases appearing in only a 
single database include 585 administrative, 323 clinical, 102 EMG, 98 ALSA, 152 VA, 111 
Peachtree North, 1,672 Medicare, and 678 mortality.  Most striking to Dr. Benatar is how 
relatively unique each database is.  There is some degree of overlap, but the majority of 
subjects in each group seem to be unique, which is somewhat troubling in terms of practicality 
of developing a registry and identifying everybody with the disease.  This suggests a need to 
search every data source, which is of significant concern in terms of getting into the 
neurologists’ offices as that may be challenging.        
 
Not a lot of analyses have been done to date, given that the investigators are still in the process 
of abstracting data, but to offer some sense of the 180 charts that have been abstracted and 
verified, Dr. Benatar reported that about three quarters of the diagnoses are verified as ALS, 
which seemed consistent with much of the other data presented during this meeting.  Interesting 
is that for the administrative database, there is a high proportion of people with an alternate 
diagnosis.  However, there are very small numbers of people in the clinical and EMG data who 
do not have confirmed diagnoses of ALS.  For those appearing in a single data source, 
approximately 30% of people have a verified diagnosis.  For those appearing in four to five 
datasets, approximately 93-94% have a verified diagnosis.  Thus, there is utility in examining 
that.  Other components that have been examined for those datasets that would permit it 
include care multiple times, specific ICD codes, EMG, et cetera.  One thing that was somewhat 
disturbing is that 323 people appeared in the ALS clinic database who did not appear in the 
Emory health care administrative database, which raises issues about the reliability of coding.                
 
Dr. Benatar’s preliminary conclusions were that it is important to identify cases from multiple 
sources, given that data sources are largely independent with respect to identification of unique 
cases; there is tremendous variability in the ease of data acquisition from different sources; 
there are methodological difficulties of data abstraction for case verification; there is potential 
importance of case verification given the high frequency of “other” diagnoses; clinical database 
diagnoses of ALS is more robust than administrative data; and accuracy of diagnosis of ALS 
varies by the number of data sources used to identify a particular individual case. 
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Discussion 
 
• Dr. Strickland suggested that this looked like an ideal set-up for a Capture-Recapture 
estimation, and he wondered if the Emory investigators had done this. 
 
• Dr. Benatar responded that they have a Masters of Public Health student who wants to work 
with this dataset to do just that.     
 
Mayo Clinic 
 
Eric Sorenson, MD 
Principal Investigator 
Mayo Clinic 
 
Dr. Sorenson noted that the Mayo Clinic pilot project is probably further along than many of the 
other pilots, given that they have fewer patients’ data to deal with.  With respect to the VA data, 
82 subjects were residing in Minnesota at the time of their VA encounter.  Of those, 29 were 
Mayo patients and 53 were other patients.  For those seen at Mayo, the charts and data were 
very easy to capture.  Of the 29 Mayo subjects, 16 were confirmed to have ALS by some 
formation of the El Escorial criteria, which is about half of that dataset.  Of the 16, 7 were 
definite, 4 were probable, and 5 were possible.  Fifteen cases were male and one case was 
female, which was not surprising coming from the VA dataset.  This marked gender imbalance 
raises a potential source of bias in the VA dataset.  There were also 13 subjects in the VA 
dataset who did not have ALS.  Many were misdiagnosed / miscoded.  The most common 
misdiagnosis was Parkinson’s disease, which is ICD-9 code 332.  ALS is ICD-9 code 335.2 so it 
is possible that there is miscoding or typographical errors could have occurred.  There were 
three other cases with ICD-9 codes similar to ALS, but which were off by a digit or so, which 
may have caused some data entry errors. 
 
From non-Mayo data sources, 52 cases of the total 82 were identified.  For the non-Mayo 
patients, the Mayo investigators partnered with the ALS Association in Minneapolis and were 
able to review their records.  As noted, there are no medical records to review within the ALS 
Association data.  The only thing that can be reviewed is whether individuals appear in this 
database as a case of ALS.  Presumably, someone somewhere has given these individuals a 
diagnosis of ALS.  Dr. Sorenson said he tended to agree with Dr. Benatar that if they were in 
this dataset, it was highly likely that they do have ALS.  From the ALS Association dataset, 19 
cases were included as confirmed.  For the other 34 cases identified from non-Mayo data 
sources, there was no clinical information whatsoever.  Some of them may have ALS, but many 
of them probably do not.  In Olmstead County, from the years 2001-2005, there were 12 
incident cases of ALS.  Only one of those was detected in the VA dataset.  Thus, it appears that 
a high number of cases are being missed by that dataset.  Using the certainty of match scale 
that scores from 1-7, in the VA dataset on which this has been done, the median score for 
certainty of match was 7 out of 7.  Thus, matching the patients up and making sure that the 
patients were correct based on the dataset received from CDC / ATSDR was not a problem.  
The range was 3.5-7.  Where they lost points was not because the data were different, but was 
almost always because a data field was missing. 
 
With respect to the Mayo experience with Medicare / Medicaid data, a dataset was received 
from CDC / ATSDR which included 1,325 subjects identified in Minnesota.  Of these, 536 were 
seen at Mayo and 789 were not.  Comparing the distribution of Mayo / Non-Mayo patients in 
Minnesota for the Medicare / Medicaid (40%) and the VA (35%), the proportion is very similar.  
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For the 536 cases seen at Mayo, 296 were confirmed as having ALS, 142 did not have ALS, 
and 98 were unknown given that there were not enough data to make a classification (these 
were Mayo cases, but they were not seen in the years 2001-2005).  Of the 296 cases that had 
codes for ALS, 192 were definite, 42 were probable, and 62 were possible.  There were 10 
prevalent cases of ALS (definite or probable) from Olmsted County, and 4 prevalent cases of 
possible ALS.  Of those Olmstead cases, 6 were incident cases in that five-year period in the 
databases, compared to 12 incident cases over the five years in Olmstead County total.  So, the 
yield was only about 50% of the cases that appeared in the Medicare / Medicaid database.  For 
the 142 cases seen at Mayo who did not have ALS, the most common diagnoses were 
Parkinsonism, PSP, and MSA.  Of these 142 cases, 10 were from Olmsted County, which 
means that for many of the cases appearing in the dataset, the diagnostic yield is very low.     
 
An analysis was conducted regarding who was in and who was out—who was the database 
missing?  Not surprisingly, those who were not in the Medicare / Medicaid database were 
younger than those who were in it.  That is one potential source of bias in using Medicare / 
Medicaid data, particularly given that one of the major prognosticators for ALS is age of onset.  
The only other demographic difference between the two groups (those in and those out of 
Medicare / Medicaid data) was their date of onset of the disease.  If someone is younger at age 
of onset, the time their disease progresses to the point that they are disabled and eligible for 
Medicare / Medicaid benefits could be delayed by a year or two.  That is, the missing people did 
not have enough time to appear in the Medicare / Medicaid dataset. 
 
The ALS Association dataset has not yet been abstracted for the Medicare / Medicaid set, but 
by extrapolation based on the VA rate, it is likely that 96 additional cases will be obtained from 
this database.  That would give them a total number of prevalent cases in Minnesota for that 
five-year period of 392.  The population in the 2000 Census for Minnesota is approximately 4.9 
million people, so roughly 500 incident cases of ALS would be expected over a five-year period.  
Thus, they might be able to yield up to 80% of the cases using the Medicare / Medicaid dataset 
by itself.  The Olmsted County yield was lower than that at 50%, but again, it may take a while 
for some of them to appear in the database.  The reality is probably somewhere in the middle of 
those two numbers, between 50-79%.  The Medicare / Medicaid dataset was far better than the 
VA dataset, which by Olmsted County yielded 8% and by the State of Minnesota yielded 7%.  
Comparing the VA dataset to the Medicare / Medicaid dataset, 4 cases were unique to the VA 
database, 12 cases were common to both, and 284 cases were unique to Medicare / Medicaid. 
 
Ongoing challenges are that up to half of the subjects in the datasets do not have ALS.  These 
are large numbers of patients, a huge amount of work to go through, and somehow to make a 
registry, the dataset must be better than what it is.  Moreover, there are many common 
diagnostic errors of other neurodegenerative disorders, most often Parkinson’s disease.  With 
respect to Olmsted County data, 10 of the 24 cases in the dataset have no evidence of ALS, or 
even ALS-like syndromes.  This means that 42% of cases in the Olmstead County dataset do 
not have ALS (95% CI: 24-61%).  One of the criticisms of Olmstead County that is true is that 
there is a low number of cases.  Thus, somewhere between 25-60% of the cases are simply not 
going to have ALS.  That is a major challenge when dealing with such large numbers and such 
a large number of resources that are required to filter through all of this. 
 
Discussion     
 
• Dr. Hornbrook pointed out that just because someone does not have ALS does not mean 
that they do not have health care needs.  A lot of symptoms were seen for these patients, so 
this is still a health care challenge that needs to be met. 
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• Dr. Sorenson replied that while this was true, it was not a health care challenge that was to 
be met within an ALS registry.  
 
 
Northwest / Hawaii / Southeast 
 
Mark Hornbrook, PhD 
Chief Scientist 
The Center for Health Research 
Northwest / Hawaii / Southeast 
 
Dr. Hornbrook explained that the HMO Research Network (HMORN) is a consortium of 15 
Health Maintenance Organization (HMO) delivery systems that have formal, recognized 
research capabilities.  These research centers are professionally autonomous from their health 
plans.  That is, the corporations do not drive the research agendas or control what the 
investigators do.  The investigators’ work is conducted in the public domain, and public domain 
work is the dominant share of their professional activities.  HMORN aims to be recognized as 
the Nation’s premier resource for population-based health and health care research; contribute 
to national and global dialogues on health research and policy; promote and establish the 
network as a preferred research partner; foster network-led collaborative studies; and share 
methodologies, best practices, and consultative expertise.  This strongly resonates with the 
NIH’s Clinical and Translational Science Awards (CTSAs ) which replace the General Clinical 
Research Centers (GCRCs).  Every one of the HMORNs has some kind of tie to a CTSA.  
 
Collaborating HMORN sites in the registry project include Fallon Health System / Meyers 
Primary Care Institute; Marshfield Clinic; Lovelace Health System; Geisinger Health System; 
Kaiser Permanente Northwest; Henry Ford Health System; Henry Ford Health System; Kaiser 
Permanente Southern California; Kaiser Permanente Northern California; and Harvard Pilgrim 
Health Care.  All of these HMOs have very important data systems, but this poses data 
collection challenges, given that there are nearly 10 million members across 9 participating 
health plans.  Therefore, consideration must be given to how to identify which charts to pull.  
Smaller HMORN sites can review medical records for 100% of cases identified via 
computerized search algorithms.  However, large HMORN sites have multiple chart rooms 
located many miles apart.  For them, the staff time and travel costs are too high to pull 100% of 
the suspected charts to review.  Thus, medical record resources must be allocated to cases that 
require additional data to determine eligibility.  Electronic data sources are multiple, and lifetime 
health record numbers enable linkage of clinical records over time for specific individuals, 
including:  Hospital discharge abstracts, electronic medical records for ambulatory care, 
ambulatory encounter abstracts, ambulatory dispensing records, home health and hospice 
records, professional and facility claims, imaging information systems, laboratory information 
systems, and death certificates. 
 
The methods used for the pilot project were to find all mentions of ALS / MND diagnoses and 
Riluzole dispenses in the electronic data systems for the period 01/01/2001 – 12/31/2005; 
eliminate “rule-out” diagnoses; keep in death certificate diagnoses; classify cases by data 
patterns into three levels of inclusion (highly likely, possible, unlikely); and validate the case 
classification algorithm against medical record data through expert review of charts.  The Center 
for Health Research has been working for years to develop a virtual data warehouse (VDW), 
which makes it efficient to compare diagnosis and procedure data across HMORN sites.  This is 
a distributed data model (DDM), which is a decentralized virtual data warehouse.  All sites map 
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local data files into standardized SAS variables (labels, formats, codes).  All the data sits locally 
under localized control.  A DDM was created to support all research projects at the participating 
sites.  Programs can be written centrally, distributed, and run by site programmers on local 
standardized data files.  The Vaccine Safety Link Data Project (VSD), supported by CDC, takes 
this one step further.  Under the public health availability of data disclosure under HIPAA, the 
VSD actually runs these standardized programs automatically, so when the data program is 
placed on the website, the various participating sites go to that website, download the program 
automatically, run it, re-post the results automatically, the originating site downloads this off of 
the website, and creates the data files with one programmer’s effort.  Cancer and ALS have not 
gone that far because there is still a lot of nervousness on the part of medical groups with 
respect to allowing data to flow that easily without somebody actually putting their eyes on the 
data before they leave a site. 
 
A validation sub-study will be conducted to test the hypotheses that there are some types of 
data patterns that should not be included as potential ALS cases, while other data patterns 
should be included.  That is, only 1 or 2 ALS / MND diagnoses should be excluded.  Many ALS / 
MND diagnoses should be included.  Procedures could identify suspect cases with no 
diagnosis.  While there is a standardized abstract, for those who have electronic medical 
records, that represents a high level of labor for someone to read the chart, transfer it onto an 
abstract form, key in the abstract form, and then run the analysis.  The Center for Health 
Research would like to open the charts electronically, print off key neurology and other records, 
and send that to the adjudicator.  This would be the actual original chart, with no other data 
processing that could have introduced error.  The sub-study will help to define the boundaries of 
the “possible” group to be abstracted and validated.  With regard to adjudication, the abstractors 
will be trained to find the appropriate sections, just as they would be trained to complete the 
abstract form.  The adjudicator will view the raw data from the chart, including EMG test results 
and graphs.  This method reduces abstractor recording and coding error.  However, Dr. 
Hornbrook noted that not all of the sites had electronic medical records during the time of this 
study.  Thus, some sites will photocopy the charts and / or will do abstraction to bring the data 
forward.  They are the ones who have to go through the process and meet the criteria for 
sensitivity and specificity.   
 
Regarding matching, data will be received from the CDC / ATSDR for the HMO catchment 
areas, which will be matched to The Center for Health Research’s case records using fuzzy 
logic methods.  Each case listing from ATSDR and the HMO can be treated as a random draw 
from the total disease population.  Tests will also determine whether both listings were likely to 
have been drawn from different populations. 
 
For preliminary tabulations, counts were combined of patients with any mention of ALS / MND 
diagnoses and / or Riluzole dispensings over the study period from eight of the nine 
participating health plans.  This includes three of the four health plans waiting to be brought in 
by new subcontracts.  This is a two-phase site, which started with five health plans and then 
added another four.  With respect to patients classified by any ALS / MND diagnosis and 
prescription, 35 patients had access to the drug but did not have a diagnosis.  In fact, one 
person had 10 dispensing or more of Riluzole in the absence of a motor neuron disease.  In 149 
cases, there were more than 10 mentions of a diagnosis and more than 10 dispensings, which 
is a predominance of evidence for those individuals.  There 2,199 cases identified on the basis 
of diagnosis alone and no dispensings.  Riluzole is in the formulary in all of the health plans, so 
it is not a question of access to the drug.  This does not even look at the issue of complication 
codes and symptom codes that would be in a cluster of disease progression.  In terms of 
patients identified by ALS diagnosis alone and dispensings, 474 cases had no ALS or Riluzole 
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dispensing, so these are other MND cases.  Six hundred ninety-four cases have only one 
mention of ALS diagnosis.  Encounters before and after these mentions are still examined to 
determine whether other corroborating symptoms or procedures will allow for classification of 
these cases in the ALS / MND group.  Data from one health system (Health System i) presented 
only whether a patient had one or more ALS / MND diagnoses or Riluzole dispenses, but not 
the actual counts of “hits.”  Therefore, it could not be combined with the other two tables. 
 
Patients by age and gender, pooling data from eight of nine of the participating health plans, 
were as follows: 
 
16
# Patients by Age & Gender
3,0976821,10690233968Total
1,77136361954620538Male
Female 1,32631948735613430
Total75+60-7445-5930-4415-29
Age Group at Reference Date
8 of 9 health plans
 
 
There were 68 cases among patients under age 30.  It is clear to see that there is an age 
progression.   
 
Patients by year of first diagnosis for eight of nine health plans were as follows: 
 
17
# Patients by Year of First Dx
8
8
8
8
8
8
7
6
5
5
1
# Sites 
3,095Total
5662005
5362004
5342003
4952002
5472001
1902000
821999
571998
611997
271996
# ALS/MND casesReference Year
Case 
Accrual 
Period 8 of 9 health 
plans
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These are unique cases classified by the year of first mention of ALS / MND diagnosis or 
Riluzole dispensing.  All cases had to have an ALS / MND diagnosis or Riluzole hit during the 
study observation period (2001-2005).  Then the investigators looked backwards to determine 
when individuals had their first mention of the disease.  There is also a set of hits in 2006, 2007, 
and 2008 so these patients do live for more than a year. 
 
Dr. Hornbrook indicated that the next steps included the execution of the subcontracts for the 
four new sites; IRB approvals for the new sites; development and validation of the computerized 
case identification algorithm at all nine sites; creation of final case listings for each site; receipt 
of data from ATSDR; matching of ATSDR-HMO case files; analyzing sources of mis-matches; 
and reporting to ATSDR.  Dr. Hornbrook emphasized the fact that there is a time lag for 
Medicare.  Medicare eligibility is automatically conferred on an ALS diagnosis.  The problem is 
that people have to wait to receive the diagnosis, which becomes a public policy issue with 
respect to depriving patients who have ALS of Medicare benefits by postponing the diagnosis.  
For some individuals, that represents a major increase in benefits.  Medicare could be the safety 
net that finds every single ALS case if people pursue their Medicare eligibility.  However, some 
people will not apply because they believe it to be welfare.  With that in mind, he viewed this as 
a health service research project because it deals with access to health insurance and how 
people get into Medicare and the VA, and why they are there and why they are not.  
 
Discussion 
 
• Dr. Benatar said it seemed that a lot of the discussion during the day had been focused on 
positive predictive value of the ICD-9 code for a diagnosis of ALS.  It seemed that The 
Center for Health Research was in a unique position to get a negative predictive value as 
well, particularly with respect to the Riluzole data.  Most of those engaged in the pilot 
projects do not have a mechanism to predict the negatives.  With respect to why people 
would be on Riluzole and not be coded with ALS, he said that anecdotally Emory has an on-
going predictive study of people at risk for ALS based on harboring mutations in the gene for 
SOD1 protein.  They have run across a few people who are carrying on-going prescriptions 
for Riluzole based on their lifetime risk of close to 100%.  While that might not explain all of 
Dr. Hornbrook’s subjects on Riluzole who have no diagnosis, it could be one explanation.    
 
• Dr. Hornbrook agreed that this was very important.  They would like to pursue this, and if 
they monitor their resources carefully, they should be able to say something about that.  It is 
important to be able to predict the negatives just as strongly as the positives. 
 
• Dr. Van Den Eeden added that anecdotally, there is a period of a year or two in which 
people with Parkinson ’s disease were interested in Riluzole, so people were taking it off-
label. 
 
• Dr. Hornbrook responded that they merely looked at dispensing, not why people took 
Riluzole.  It is possible that there is off-label dispensing, even inside the HMOs. 
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Wendy E. Kaye, PhD 
Senior Epidemiologist 
McKing Consulting Corporation 
 
During this session, Dr. Kaye led participants in an open discussion regarding the issues related 
to developing a national surveillance system and registries for ALS and MS. 
 
Discussion 
 
• Dr. Hornbrook wondered whether anyone planned to work on negative prediction models 
and criteria for defining when a person does not have ALS.  
 
• Dr. Sorenson responded that this was a very active interest for the Mayo Clinic.  With their 
data from Olmstead County, they can generate very good predictive models on who does 
and who does not have ALS.  They are very interested in determining who they are missing 
and who is appearing in the database who does not have ALS.    
 
• Mr. Culpepper responded that the MS Center of Excellence is attempting to do this with the 
MS side as well.  The intent of their original strategy was to focus on those who were in the 
system, but who were not MS. 
 
• Dr. Tyry indicated that in NARCOMS there is a very small percentage of people who have 
reported being misdiagnosed.  It might be helpful to examine the characteristics of those 
individuals as well.   
 
• Dr. Sorenson responded that that was yet another challenge.  That represents a population 
of patients for whom one neurologist may say that have the disease, while another may say 
they do not.  That is a different scenario from people who are miscoded or appear with 
another diagnosis.  Determining what to do when there is a disagreement between clinicians 
is an even greater challenge. 
 
• Dr. Van Den Eeden replied that partially it would depend upon when they wanted to say 
someone was a case or not a case.     
 
• Dr. Kasarskis recapped what he believed he understood, in no particular order, from the 
morning’s presentations:  It seems clear that one dataset clearly does not serve all masters.  
While life would be simpler with a biomarker or a set of biomarkers, at least from the ALS 
side, they do not have this.  Thus, the goodness of anyone’s datasets rests on how good 
one’s diagnostician is.  Several people mentioned that they had an adjudicator (e.g., an 
expert).  Bertrand Russell said an expert is a person that other experts say is an expert.  
From his own experience reviewing charts from many places around the country in the 
context of the VA registry, Dr. Kasarskis found that there were some people who were 
clearly not experts and others who clearly had seen a lot of ALS, zeroed right into the heart 
of the matter, and laid out a perfect history.  Yet, someone must try to reduce that to a single 
code in a single dataset, which is an extremely difficult and perhaps impossible task.  With 
Open Discussion Session 
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no offense to anyone, he did not believe they would really further anybody’s agenda by 
trying to invent new terminology, especially that equivocated on the same words.  El 
Escorial is really not a perfect system, but to some degree, they have already co-opted the 
terms “possible,” “definite,” and “probable.”  To come up with another definition in another 
study is not going to allow any sort of cross-comparison whatsoever.  Instead, it will cloud 
the water and people will never move beyond the debate about what they are really talking 
about in terms of a dataset.  He also wondered what the goal was for the entire exercise.  If 
they wanted a dataset of people for whom there are very few false positives, meaning really 
true cases, then that would feed into a clinical study.  If they wanted to determine a 
spectrum of motor neuron diseases to find out who was in the population, that would be a 
different set of questions that would allow “fuzziness” in the dataset.  There was no right or 
wrong answer, he just wondered why they were collecting the data and what they were 
trying to monitor.  He thought that the European approach was to call it “motor neuron 
diseases” of which classic ALS is a subset.                
 
• Regarding the definitions, Dr. Kaye agreed with Dr. Kasarskis about the El Escorial criteria.  
However, surveillance also has definitions of “definite,” “probable,” and “unlikely.”  They do 
need to be careful about what they say and perhaps should included a descriptor in front of 
it, but as far as these projects are concerned, those terms are going to be used.  For 
surveillance purposes, they are definitely ALS, probably ALS, or they are not likely to be 
ALS.  There also must be an understanding that people can shift categories as more years 
of data become available.  Regarding the other motor neuron diseases, CDC / ATSDR did 
ask for all of those disease categories because they thought it would be a global process.  
Unfortunately, so far it appears that a lot of the other MND codes are being used 
inappropriately.  In South Carolina, 50% of the cases were coded as other motor neuron 
diseases because they are using the codes as descriptors of symptoms and not diseases.  
However, they are not doing that with ALS.         
 
• If they were to do this again, Dr. Sorenson wondered whether they would include the ICD-9 
code 335.2.  A small minority of those cases have ALS. 
 
• Ms. Royer said from what they have found so far, the majority of the other and unspecified 
motor neuron disease codes (335.29, 335.2) are not turning out to be ALS cases when they 
are the only code that identified that case.  There also appears to be very few instances 
when pseudobulbar palsy or progressive muscular atrophy is the only code that identifies an 
individual for inclusion in the cohort, and upon chart review it appears to be a potential ALS 
case.  It appears that pseudobulbar palsy and progressive muscular atrophy are being used 
to describe symptoms of other diseases. 
• Dr. Sorenson pointed out that they could enrich their database by culling those out of the 
population. 
 
• Dr. Kaye added that there could also be other descriptors that could better sort those out 
ahead of time. 
 
• Mr. Culpepper noted that another issue was that every dataset is unique in terms of the 
types of data that are available.  Therefore, what can be done in one dataset to rule out 
cases is not necessarily going to be available in another dataset.  For each of the data 
sources they will have to develop specific algorithms that are pertinent to that data source, 
with which everyone is comfortable, and that are giving them a reasonable estimate of who 
the real cases are.  If they can do that, they can prioritize the cases as definite, probable, 
and possible or something along those lines based upon the strength of evidence within that 
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given data source.  Once the matching is done, they will be able to examine the ratings 
across datasets to help further define what is definite, probable, and possible.  
 
• Dr. Benatar pointed out that within a dataset, defining cases of ALS rests on the 
fundamental premise that there is agreement about when to abstract a chart, which is the 
gold standard.  Thus, there probably should be some discussion about whether they will rely 
on El Escorial criteria or whether other criteria will be used.  Perhaps they will want to have 
several levels of confidence of diagnosis, including El Escorial and then some gestalt 
impression based on several features that are included.  If they do not have agreement on 
what rules should be used when abstracting data to make those determinations, all of the 
other algorithms that are tested against any gold standard will not be meaningful.       
 
• Dr. Kaye referred people to the Excel data sheet the projects are to send back to CDC / 
ATSDR, noting that there are two columns:  one for the neurologist and one for El Escorial 
criteria.  Those are different. 
 
• Dr. Benatar said that the neurologist is still making the determination about El Escorial 
criteria. 
 
• Dr. Kaye responded that they are not because they do not have the data that would feed 
into the El Escorial criteria, so they cannot use it at all. 
 
• Dr. Stricker said that of the 400 charts he has reviewed, the El Escorial criteria are used in 
about 12 of those. 
 
• Dr. Benatar said that meant he was making a gestalt judgment for the other field, but the 
question regarded what that gestalt judgment was based on and whether it was the same as 
the gestalt judgment of other investigators.   
 
• Dr. Sorenson pointed out that as the algorithm becomes more complicated, they start 
missing data as it builds.  A simple, straightforward program is needed.  Perhaps less than 
5% of neurologists who see patients who have been diagnosed with ALS for a second 
opinion change the diagnosis.  He would also argue that if any neurologist gave a patient a 
diagnosis of ALS that would be good enough.     
 
• Dr. Benatar clarified that what he was saying was that they need to have consensus on the 
subject.  Perhaps someone could propose some rules for them all to consider. 
 
• Dr. Newman said he thought in essence that was what was happening during this 
discussion in slow motion.  That is, a number of programs are underway simultaneously 
which are examining large databases in different ways and attempting to determine the most 
efficient way “to be wrong the least”.  While the point was well-taken with respect to 
terminology, given the opportunity to review everything in the chart, investigators may be 
able to make a determination.  However, they must be able to look at 500,000 pieces of 
Medicare data and 1.4 minutes later be able to say what the set is that has a high likelihood 
of being ALS.  He thought it was Don Moulder who said that it was rare for somebody who 
was experienced to look at ALS and think it could be anything else.  The simplicity of that is 
in great contrast to the tortured efforts of El Escorial, as well as the El Escorial revised 
criteria in which many people are still dying without meeting “definite.”  There are going to be 
false positives and false negatives, but if a neurologist says someone has ALS, that is one 
of the best predictors.  
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• Dr. Benatar expressed concern about the emergency department physician who states that 
there is a history of ALS. 
 
• Dr. Newman responded that the emergency department physician is likely to have more 
than one data point in that same database. 
 
• Dr. Sorenson pointed out that some of the centers were grappling with the fact that they 
have isolated data points and they have to make a decision about whether a patient is in or 
out.   
 
• Dr. Hornbrook’s sense was that they would have to make do with all of the data they could 
possibly get.  He will have some cases for which he has only one or two data points.  That is 
going to be a class of cases that will be labeled accordingly.  But, that’s not all of his cases.  
A lot of cases will give them two or more years of a progression of symptoms, treatments, 
and co-morbidities that combined will give them the gestalt and perhaps even more than 
that. 
 
• Dr. Benatar agreed that some cases would be easy, while others would be more difficult.  All 
he was suggesting was that an agreed upon set of principles should be used for the hard 
cases.  Otherwise, they would not be speaking the same language.  When there is clear 
evidence of progression, they have ALS, they are on Riluzole, et cetera, then they can be 
included as definite ALS.  He was talking about the more difficult cases in which a judgment 
must be made because there is a lack of data or there is just one data point. 
 
• From the health services research perspective, Dr. Hornbrook said he had sometimes had 
few data points because the patient had tremendous barriers to access.  If the person has 
very good access, they present all of the time for their migraines, foot aches, muscle 
problems, joint problems, et cetera and if there is only one ALS mention he is a lot more 
suspicious.  He does not believe that the abstraction data set is preferred for neurologist 
adjudication, which is why they are staying with the full medical record context in their 
adjudication approach, because they want all of the environmental information. 
 
• Dr. Benatar suggested that they should have agreement upon whether they should or 
should not be using a data abstraction form.  That seemed to be the extent of the 
disagreement.    
 
• Dr. Kaye responded that the projects were somewhat different from each other for a reason.  
CDC / ATSDR does understand that there will be some differences because many of the 
HMOs have electronic records and, therefore, do not have the issue of having to do data 
abstraction versus a more traditional setting where data abstraction must be done. 
 
• Dr. Benatar suggested that the minimum requirement should be that each site should write 
down the rules they are using.  
 
• Dr. Kaye indicated that they reviewed a number of the cases in South Carolina, which 
showed  their rationale for why cases were included in one category or another and it is 
more of a gestalt. 
 
• Dr. Sorenson asked Ms. Royer what portion of the patients they uncovered who had ALS 
from a single emergency department visit for pneumonia, which had no documentation of 
anything else from these isolated data points. 
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• Ms. Royer responded that she did not remember the number right off, but sometimes the 
only chart she had available was one emergency department record from which to try to 
confirm a case. 
 
• Dr. Sorenson said his gestalt was that those numbers are fairly low, and they are struggling 
with a lot of time and effort over a very small fragment of patients and whether it is going to 
make or break the database.  It is almost an insignificant group of patients.   
 
• Dr. Benatar pointed out that if investigators had a death certificate and some other source to 
make the diagnosis of ALS, they could not then go back to say that being identified in two 
data sources meant they have ALS.  That just becomes circular.   
 
• Dr. Sorenson responded that they went through the VA and to the Medicare database, 
finding that in the vast majority of cases it is obvious—they have ALS or they do not.  Only in 
a small number of cases did they have to struggle to determine whether a patient had ALS 
or not.   
 
• Dr. Stickler said that of the 135 records he reviewed in South Carolina with an ALS or late 
ALS code, 51 did not have enough information and 36 had enough to be probable or 
possible, but not to be definite.  As he has reviewed these, he has been making notes in the 
text box about why he thought someone could have ALS and is hoping to go back to create 
parameters.    
 
• Ms. Royer added there were 10 cases out of the 135 reviewed to date where the diagnosis 
of ALS appeared in the chart, but there was not enough clinical data to confirm a case. 
 
• Dr. Sorenson replied that they were struggling with a really small number.  Just like anything 
else, to increase diagnostic sensitivity and specificity, as they move toward 100%, their 
costs are going to skyrocket.  At some point, they have to live with what is financially 
possible and how much sloppiness they can live with.  A huge amount of effort can be put 
into tracking down a handful of cases, or they can focus on what is reasonable.  There is no 
way in a national registry that charts can be perused to this level to decide if a case should 
be in or out. 
 
• Dr. Benatar pointed out that that was why this was done at the feasibility stage, in order to 
know the reliability of the data sources. 
 
• Dr. Cwik said it seemed to her that everybody should be using the same definitions and the 
same criteria.  If not, they would not be able to compare the datasets or pool the data.  This 
would destroy the registry. 
 
• Dr. Strickland agreed with Dr. Sorenson’s comments about what a small proportion of ALS 
patients this is going to be, but at the same time he had 3.2 million patients at Kaiser. 
 
• Dr. LaRocca found it surprising that in a project like this there was not more agreement on 
definitions.  Epidemiology is really all about approximations.  They really are spending a 
great deal of time on trying to achieve what would seem to be perfection.  Instead, they 
need to devote more time to looking at the sources of error and defining what the 
parameters of the errors are in the various estimates because they really do not have the 
time or resources to achieve perfection or anything near it.  What they really need to know is 
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how good their approximations are.  They also must keep in mind that they are trying to 
achieve a reasonable approximation, at a reasonable cost, within a reasonable period of 
time. 
 
• Dr. Newman asked how Dr. LaRocca would suggest getting an idea of how wrong they are.  
As they heard earlier, the reasons they are doing this is to know what the range of incidence 
is in order to know when there is a cluster.  Without knowing how much “slop” is built in, it 
was not clear they would be able to answer that question. 
 
• Dr. LaRocca responded that a good example might be the study that Mr. Culpepper showed 
them in which they developed an algorithm and then tested it on a sub-set of the available 
dataset.  That is probably the most cost-effective way to examine the level of errors, as long 
as the sub-set is reasonably representative of the larger population. 
 
• Dr. Kaye indicated that Dr. Randy Durbin, who is a statistical consultant, will be working on 
some methodology.   Basically, through capture-recapture statistics, he will study where the 
overlap is, which will allow for making best estimates on what has been found.  Dr. 
Strickland did this with the Parkinson’s data in Nebraska.  It is based on fish and wildlife, but 
specific applications have been designed for use in public health.  That is one thing they will 
be doing with the combined datasets that might help answer some of those questions.  They 
must keep in mind that surveillance is never perfect and that they will always be missing 
somebody.  It would be nice to know some characteristics of the kinds of people they are 
most likely to be missing.     
 
• Mr. Culpepper pointed out that the other issue pertained to how they would use that 
information.  If the datasets are categorized as definite, probable, and possible, for some 
questions they may only want to focus on the definites.  If examining raw incidence, they 
may want to include everybody in order to get a range of what the real values are.  Even if 
there is some disagreement or question about some of the cases, once they are identified, 
there is no reason to discard them per se. 
 
• Dr. Benatar suggested three questions to ask during data abstraction to make a 
determination:  1) Is there a chart diagnosis of ALS?  That weeds out the question of 
miscoding, so a Parkinson’s patient can be quickly dispensed with; 2) Has a diagnosis of 
ALS been made by a neurologist?; 3) Is there an El Escorial diagnosis of ALS at the various 
levels of certainty.   
 
• Dr. Kaye responded that all of those questions are in the Excel data:  1) “What was the code 
in the chart?”; 2) What were the El Escorial criteria; and 3) For each diagnosis it asks 
whether it was made by a neurologist, family medicine practitioner, et cetera.  Procedure 
codes were originally considered as well, but that went beyond the scope.  
 
• Dr. Benatar said the chart was unlikely to have a code, which was why the question should 
be, “Is there a chart diagnosis of ALS?”  It was not clear to him how the Excel could be 
completed if the abstraction was first. 
 
• Dr. Kaye replied that the Excel is the sum of what is found. 
 
• Dr. Benatar stressed that they would have to generate that automatically from the 
abstractions because otherwise they would have to go back and abstract again. 
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• Dr. Kaye acknowledged that they must ensure that there is no disconnect between the 
abstraction forms versus the Excel.  She thought it was possibly just a terminology issue. 
 
• Dr. Tyry expressed an interest in going back to the databases to look for people who 
reported being misdiagnosed.  Most of the data they have is self-report, so she was unclear 
how reliable that would be, but self-reports are considered as cases.  They do ask whether 
they have a doctor’s diagnosis. 
 
• Dr. LaRocca said they had done some verification and self-report was not that unreliable. 
 
• Mr. Culpepper said they see the same thing in their survey data and do ask whether there is 
a physician diagnosis. 
 
• Dr. Kasarskis said that in the VA registry, they apply a screener asking, “Has any health 
care provider told you that you have ALS or any motor neuron disease?” 
 
• Dr. Sorenson noted that the MS group was much further along than ALS.  He did not believe 
ALS should hold themselves to a different standard from what MS has done.  He thought the 
same rules should be applied to ALS as had been applied to MS.  
 
• Dr. Teter indicated that they are also tracking number of relapses, how often relapse occurs, 
et cetera.  She would not doubt the neurologists’ diagnoses. 
 
• Dr. Kaye pointed out that even though the MS registries were at two extremes with one 
registry being almost entirely clinical diagnoses and the other entirely self-report, they were 
getting similar results. 
 
• Dr. Hornbrook thought that end-of-life care required documentation from hospice. 
 
• Dr. Kaye clarified that for Medicare eligibility is determined prior to admittance to long-term 
care.  They do not have to put a diagnosis code in the field in order to get paid.  In some 
states, there was 100% ICD coding in long-term care while in other states there was no 
coding.  Long-term facilities are not required to indicate a reason for eligibility. 
 
• Dr. Benatar wondered if everyone was in agreement that someone should be included if 
their hospice record indicated that they had ALS. 
 
• Mr. Culpepper thought that would be okay, but that it should be documented in some other 
way also. 
 
• Dr. Hornbrook pointed out that another issue pertained to who was filling out the codes and 
why.  A clerk following the coding rules was different from trying to drive the care system 
with the correct data. 
 
• Dr. Sorenson said he stood by accepting a diagnosis from a neurologist. 
 
• Dr. Thurman pointed out that, with respect to self-report, one issue of concern was that even 
if asked whether the doctor who made their diagnosis was a neurologist, some people may 
not know what kind of doctor they saw. 
 
• Dr. Sorenson stressed that doctors are afraid to make the ALS diagnosis. 
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• Mr. Culpepper said that in the VA system, most people develop ALS while active.  If they 
present to VA after a definitive diagnosis is made, the investigators can work backward and 
forward from that point to validate whether the diagnosis is a true case. 
 
• Dr. Kasarskis agreed with Dr. Sorenson that rarely would a primary care physician diagnose 
ALS.  Every one of these cases has two or three other diagnoses and physicians (e.g., 
primary, ENT, orthopedist, rehab) along the way before the “light bulb goes on.”  His 
prediction was that there would be a lot of ICD-9 codes before an actual ALS diagnosis. 
 
• Dr. Teter said that while they see cases in the MS clinic, people go back to primary care for 
treatment.  They suspect that a portion of registrants lost to follow-up may be treated in 
primary care. 
 
• Dr. Tyry said they do not know who their responders treating physicians are, but they do ask 
people if their care is taking place in a specialized MS center or clinic.  About half say “no.”  
Not everybody sees a neurologist every six months. 
 
• Dr. Sorenson thought the same would be true in ALS.  Probably about half present to a 
clinic and the other half are seen locally by their family physician and / or neurologist.  
Probably all were diagnosed by a neurologist. 
 
• Dr. Hornbrook said they see a pattern of patients with early symptoms.  It is likely that family 
physicians try many things until a family grows increasingly angry.  Then they go to the 
neurologist.  He has seen patients go outside Kaiser to a university and then send Kaiser 
the bills. 
 
• Dr. Kaye inquired as to how many of the investigators had had an opportunity to examine 
any of the pharmacy data. 
 
• Dr. Hornbrook stressed that pharmaceuticals can tell them a great deal about what a 
physician believes their patient to have. 
 
• Mr. Culpepper said that within the VA, there are safeguards.  All DMT are non-formulary, but 
usually require a sign-off.  They did not use Mitoxantrone as a criterion for DMT usage 
because it is used for other things.   
 
• Dr. Kasarskis pointed out that the absence of prescribing something did not mean anything. 
 
• Dr. Kaye wondered if service-connection for MS or ALS was a reliable indicator by itself.  
 
• Dr. Kasarskis thought that there should be greater caution with respect to the service-
connection label.  It could be granted on exam by a nurse practitioner or a retired physician 
versus an A-team making this designation.  The encounter is somewhat different in the VA 
in that people are presenting to be certified as service-connected in order to receive 
benefits.  It is a legal encounter rather than a health care encounter.  Merely to say 
someone is service-connected is not enough to determine whether someone is a case.  The 
first criterion of being diagnosed by a neurologist and / or being on DMT are fine, but he did 
not endorse making a decision based simply on service-connection.    
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• In thinking about the long-term, Dr. Kaye requested discussion about the grayer area of 
cases in disease progression and how that might affect whether someone is included in 
“definite” or “possible.” 
 
• Mr. Culpepper replied that one problem with the MS data in the VA is that they do not have 
this information in the extant databases.  They have diagnosis codes, procedure codes, 
pharmacy use, and service-connected status, but not sub-type.  They have to use survey 
and direct data collection efforts to garner that information.  They do not even have date of 
onset or date of diagnosis to be able to calculate disease duration and use that as a proxy, 
as poor as it may be. 
 
•  Dr. Kaye clarified that she was referring more to not becoming known to the system until a 
certain stage of illness, meaning that they were missing people early on because they are 
not identified this way.  For the VA data, for example, someone had to be included every 
year as having MS, but someone may receive a diagnosis and then not have another one 
for 15 years. 
 
• Mr. Culpepper responded that when they applied the algorithm, it did not matter what year 
someone was prescribed DMT or what year they may have received a service-connected 
disability.  The investigators wanted to know whether someone had a primary diagnosis for 
MS once per year.  If somebody was diagnosed with MS in 1999, did not have another 
diagnosis for MS for two years, and then suddenly had a diagnosis and a DMT, they would 
be retrospectively pulled into the cohort back to 1998 even if that was prior to a definitive 
diagnosis.  This is not known for everyone currently, except for the survey respondents. 
 
• Dr. Teter said that they have found diagnoses of clinically definite MS for people who are in 
their 50s or 60s who may have had MS for 20-25 years, but perhaps not diagnosed because 
it was relapsing-remitting.  They may have gone to someone for the symptoms or may have 
ignored them.  The point being that no matter what the investigators do, they will be 
underestimating how many people actually have MS. 
 
• Dr. Tyry noted that neurologists may not correctly document the type of MS.  Based on the 
validation study, it seemed that the patients were better able to report that than the 
neurologists in some cases.  That was one reason they did not use the categories of 
“primary progressive” and “secondary progressive.”  Instead, they describe what happens in 
the disease history in terms of relapse, worsening symptoms, et cetera. 
 
• Dr. Sorenson said the same was true for ALS.  Referring to a manuscript in which Dr. 
Kasarskis was involved, which examined the correlation between neurologists and their El 
Escorial diagnostic criteria and found that there was only a 60% concordance rate between 
the neurologists and how they classified people as possible, probable, and definite ALS. 
 
• Dr. Kaye requested that panelists discuss the lack of overlap in a lot of the databases. 
 
• Dr. Benatar indicated that Emory has about 8-9 data sources, which seem largely 
independent although there is some overlap.  There is some overlap found by going into 
community neurologists’ offices, but they are largely independent.  If one of the goals of the 
registry is not only to have accurately diagnosed cases, but also all of the cases, it makes 
him nervous about what will need to be done to get to all of those cases. 
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• Dr. Kaye asked whether that argued for a self-identification component with the stipulations 
that had already been made.  That is, someone could self-identify and state whether and by 
whom they were diagnosed. 
 
• Dr. Benatar thought there was already a marker of self-identification in those who register 
with ALSA.  That is a relatively small number in Georgia.  Emory had more people in their 
ALS clinic, so he worried about whether self-identification would be sufficient. 
 
• Ms. Usher said she was surprised at the numbers who had registered with ALSA, although it 
was not clear to her why it was so low.  There were 189 based on her review of ALSA’s 
records.  She thought self-report was fine, but it will potentially miss people. 
 
• Dr. Benatar wondered about the potential for selection bias based on how the investigators 
choose which charts to abstract, and whether there was something self-fulfilling about where 
they were headed if they were doing most chart abstractions from tertiary referral centers 
that were highly specialized in ALS care.  Those people identified at Emory may not have 
the same profile as those people who are diagnosed elsewhere.  They will get at that to 
some extent by moving around different institutions throughout the US, and that the HMO 
data will address that to a large extent, but it is still troubling.  
 
• Dr. Kaye responded that South Carolina is abstracting nearly 100% regardless of where 
people are. 
 
• Dr. Benatar noted that South Carolina is having the problem of incomplete data to be able to 
decide whether someone has ALS.  In a tertiary referral center there is a bias in the 
population, but there is a more reliable diagnosis.  In other facilities, perhaps the diagnosis 
is less reliable.  This may be a tension that cannot be resolved. 
 
• Dr. Hornbrook pointed out that the problem with proving the negative is that it is extremely 
expensive to draw enough charts to prove the null hypothesis that there are no cases.  At 
the same time, they would have the opportunity to examine the negative prediction to look at 
various patterns of near case criteria:  no mention of the right drug, no mention of the right 
disease, but a symptom complex that would lead one to suspect cases.  This might result in 
a subset of cases which would be most rich for finding missed cases. 
 
• By asking about Rilutek® use, Dr. Kasarskis noted that they had not heard anything about 
utilization of medical resources and how that changes over time.  That is essentially a 
surrogate marker for the veracity of the ALS diagnosis.  When people with ALS are first 
diagnosed, they usually do not have power wheelchairs, walkers, et cetera.  However, as 
time goes on they do.  Bob Miller’s group had at least an abstract showing the cost of ALS 
annually by ALS functional rating scale.  That definition included lost wages and lost benefits 
for the patient and caregiver.  While Dr. Kasarskis realized that this was detailed economic 
data, certainly some of these commonly used assistive devices appearing in a new person 
could help verify or disprove some of the codes.   
 
• Dr. Kaye said that one thing that is in a holding pattern awaiting finances, CMS is willing to 
give ATSDR every encounter for the individual once that individual has been identified 
regardless of whether MS or ALS was mentioned within one of the 10 ICD-9 codes.  This will 
enable them to see patterns of usage.   
 
• Dr. Kasarskis responded that this will not work for MS because the drugs actually work. 
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• With respect to what information associations have, Mr. Gibson noted that if they were to do 
this study differently, they would have more of a comprehensive look.  From what he 
gathered from the three ALS studies, they went to the chapter that dealt with the clinical 
person.  Because of government silos, there was not enough time for collaboration to have a 
full ascertainment of the resources available.  Within each chapter there are various silos.  
For example, there is a silo of advocates from the State of Georgia who are not part of the 
chapter and do not need resources for whatever reasons.    
 
• Dr. Kaye noted that one issue in particular with ALSA was that they had to go to every 
chapter; whereas, with the National MS Society, they could go to one location.   
 
• Ms. Kennedy requested clarification of what information they were requesting from ALSA.  
 
• Dr. Kaye responding that they were asking for any information they could get (e.g., the 
number of people with that diagnosis in a state, names, dates of birth, et cetera) so that they 
can be matched with the other datasets and the final dataset can be de-duplicated as much 
as possible, with the understanding that there may still be duplicates. 
 
• Dr. Van Den Eeden added that some people will steal someone’s health card, so the data 
gets in for multiple patients under the same health record number.  It takes a lot of detective 
work.  They are now requiring people to show their ID when checking in to see the doctor. 
 
• Mr. Culpepper indicated that they have not done any matching in the VA.  Everything is 
connected by Social Security Number.  They have found some errors and some 
transposition takes place.  Surprisingly in that large a system, this does not occur with great 
frequency.  The issue will really come into play when attempting to link across systems.  
 
• Dr. Gunter said that New Mexico is involved in the development of an information exchange 
across organizations, so there are a number of published algorithms.  There are various 
types of software that can take different constellations of variables and use them for 
matching.  She wondered what South Carolina used to do their linkages. 
 
• Ms. Royer responded that they use a statistical algorithm. 
 
• Dr. Durbin indicated that CDC’s Division of Cancer Prevention and Control (DCPC) had 
done a remarkably good job of matching, and in the last four years they have developed 
some in-house software that they share freely:  The Link Plus product does the probabilistic 
matching.  It is an easy to use stand alone application which can detect duplicates or link 
files.  Although originally designed to be used by cancer registries, it can be used with any 
type of data.  It has a large amount of flexibility in that it will allow weights to be assigned to 
the algorithms thought to be most appropriate for the specific data and data types.  He 
encouraged everyone to think about what was available that had already been paid for by 
taxpayer dollars.    
 
• Concern was expressed about the emphasis on European style names.  A lot of people in 
Southern California are Asian.  Asian women customarily change their names upon getting 
married, although they will sometimes follow the American custom.  Sometimes the Chinese 
characters that make up an Asian name will be put together as two syllables.  Sometimes 
they will be a first name and a middle name.  Frequently, the Latinos will use the maternity 
along with paternity.  This is very complicated.   
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• Dr. Teter indicated that the way their algorithm is set up, they can do matches up to five or 
six points, but then the last name does not match.  This requires further discussion.  Their 
analysts suggested adding more levels because it has more quality if it contains the last 
name.  Someone who scores a three, four, or five regardless of whether the last name is 
included, it has to be more definite.  Scoring one point each on sex, state, city, and date of 
birth will result in a score of 4 but then the last name does not match up.  With a group of 
5,000 people with a score of 4, New York’s argument was that they need more layers in 
order to ascertain whether a 4 is a match with the last name. 
 
• Dr. Tyry suggested trying the program to which Dr. Durbin referred and weight the last name 
more heavily rather than creating more levels. 
 
• Dr. Kaye clarified that the score was supposed to be done after the link.  The idea was that 
a human matched them up and the score was assigned afterward.  A human should not be 
assigning people with different last names as a match to start with unless they had data to 
show that one was a maiden name. 
 
• Dr. Teter indicated that their system is automated.  It reads everything, matches according 
to the algorithm, and assigns a score to it.  At this time while preliminary testing on matching 
is being done by last name, she is not sure whether the matches are correct.   
 
• Dr. Kaye pointed out that New York was using this differently than it was intended.  That is, 
it was to determine how good the match was after it was made, versus using it to make the 
match. 
 
• Dr. Tyry indicated that NARCOMS did the first name, last name, and date of birth one at a 
time.  Once those three are down, everything else seems to fall into place.  There are very 
few other combinations that will result in additional sure matches. 
 
• Dr. Teter said that New York had thought about starting with last name, but MS being a 
disease that affects people primarily in their 20s, there is a high likelihood of women getting 
married.  Thus, matching on last name to begin with would miss a population. 
 
• Dr. Gibson inquired as to what the plans were to do the updates of the ATSDR studies that 
address  ALS and MS. 
 
• Dr. Kaye responded that the written study information has been updated with all of the data 
for both the MS and ALS projects.  A new fact sheet was needed, which she spent a lot of 
time updating, but then she and Dr. Muravov were told that the correct format had not been 
used.  They then spent an inordinate amount of time converting it into a different format with 
a lot less information in it.  They will get it cleared through the system so that it the updated 
fact sheet can be posted. 
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In conclusion, Dr. Kaye indicated that this group would likely not meet again until there were 
data in from the projects.  The plan was for ATSDR to conduct some analyses of the combined 
datasets, with some analyses done on the individual site levels.  Additional experts in the areas 
of MS and ALS will be brought in to discuss the issues, with perhaps more concrete information 
pertaining to whether they should proceed on the same path or if changes would need to be 
made.  Those will be the suggestions that ATSDR is seeking in order to move forward with an 
ALS registry and MS surveillance.  Based on when ATSDR expects to receive data from all of 
the pilot projects, most likely the next meeting will be around May 2009.  In order for ATSDR to 
plan around other annual meetings / conferences, she requested that panelists email her with 
specific dates of ALS or MS conferences that people might be attending.  Dr. Kaye thanked 
everyone for their attendance and all of their work on this project.  With no further business 
posed, she officially adjourned the meeting.    
Closing Remarks 
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